

CITATION REPORT

List of articles citing

Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III

DOI: 10.1016/j.schres.2005.07.014

Schizophrenia Research, 2005, 80, 19-32.

Source: <https://exaly.com/paper-pdf/39450400/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
944	Metabolic syndrome and cardiovascular disease. 2005 , 19, 84-93		70
943	Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study. 2005 , 27, 1930-41		41
942	P.3.c.050 Psychopathology and metabolic syndrome (MS) in psychotic patients: the CLAMORS study. 2006 , 16, S423-S424		
941	P.3.c.051 Is risperidone an atypical antipsychotic?. 2006 , 16, S424		
940	P.3.c.052 Quetiapine monotherapy is efficacious for depressive episodes of bipolar I and II disorder: a confirmatory double-blind study (BOLDER II). 2006 , 16, S424-S425		
939	Long-term treatment with atypical antipsychotics and the risk of weight gain : a literature analysis. 2006 , 29, 303-19		90
938	Second-generation antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles?. 2006 , 29, 587-98		65
937	Higher fasting serum insulin is associated with increased resting energy expenditure in nondiabetic schizophrenia patients. 2006 , 60, 1372-7		10
936	Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. <i>Schizophrenia Research</i> , 2006 , 83, 87-93	3.6	229
935	Are females at special risk of obesity if they become psychotic? The longitudinal Northern Finland 1966 Birth Cohort Study. <i>Schizophrenia Research</i> , 2006 , 84, 15-9	3.6	22
934	Higher fasting serum insulin levels are associated with a better psychopathology profile in acutely ill non-diabetic inpatients with schizophrenia. <i>Schizophrenia Research</i> , 2006 , 86, 30-5	3.6	14
933	Differential trends in prevalence of diabetes and unrelated general medical illness for schizophrenia patients before and after the atypical antipsychotic era. <i>Schizophrenia Research</i> , 2006 , 86, 99-109	3.6	29
932	Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. <i>Schizophrenia Research</i> , 2006 , 86, 15-22	3.6	389
931	Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. 2006 , 45, 771-91		298
930	Genetics of antipsychotic treatment emergent weight gain in schizophrenia. 2006 , 7, 863-87		127
929	Alta prevalencia de s�ndrome metab�lico en pacientes esquizofr�nicos: una revisi�n de la literatura. 2006 , 13, 127-135		1
928	Dislipidemias e antipsic�ticos at�picos. 2006 , 55, 296-307		1

927	Are we treating schizophrenia effectively? Understanding the primary outcomes of the CATIE study. 2006 , 11, 1-13; quiz 14	5
926	The standard of care in suicide risk assessment: An elusive concept. 2006 , 11, 442-5	4
925	Clinical trials in schizophrenia with results for the real world. 2006 , 11, 9-13	8
924	Metabolic findings from the CATIE trial and their relation to tolerability. 2006 , 11, 32-9	45
923	Incidence, prevalence, and surveillance for diabetes in New York State psychiatric hospitals, 1997-2004. 2006 , 57, 1132-9	17
922	Epidemiological impact of antidepressant and antipsychotic drugs on the general population. 2006 , 19, 405-10	9
921	Prevalence of the metabolic syndrome in veterans with schizophrenia. 2006 , 12, 5-10	35
920	Schizophrenia, Antipsychotics, and the Metabolic Syndrome: Is There a Silver Lining?. 2006 , 163, 1132-1134	25
919	Medication-induced weight gain and dyslipidemia in patients with schizophrenia. 2006 , 163, 1697-704; quiz 1858-9	29
918	Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring. 2006 , 21 Suppl 2, S11-5	76
917	Mortality in schizophrenia. 2006 , 15, 873-9	92
916	Antipsychotic drugs and diabetes--an application of the Austin Bradford Hill criteria. 2006 , 49, 1467-76	48
915	What have we learned from CATIE about the pharmacologic treatment of schizophrenia?. 2006 , 4, 35-39	
914	A UK audit of screening for the metabolic side effects of antipsychotics in community patients. 2007 , 33, 1397-403	103
913	Review: Severe mental illness, antipsychotic drugs and the metabolic syndrome. 2006 , 6, 199-204	5
912	Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. 2006 , 2, 14	129
911	A perspective on the emergence of meditation techniques for medical disorders. 2006 , 12, 709-13	3
910	Differential pharmacology of atypical antipsychotics: clinical implications. 2007 , 64, S3-8; quiz S24-5	14

909	Memantine-associated reversal of clozapine-induced weight gain. 2007 , 40, 149-51	12
908	The CATIE schizophrenia trial: results, impact, controversy. 2007 , 15, 245-58	89
907	Obesity and metabolic syndrome in a psychiatric rehabilitation service. 2007 , 41, 606-10	62
906	A case series: evaluation of the metabolic safety of aripiprazole. 2007 , 33, 823-30	52
905	Severe mental illness and risk of cardiovascular disease. 2007 , 298, 1794-6	286
904	Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics. 2007 , 41, 1593-603	46
903	Balancing efficacy and safety in treatment with antipsychotics. 2007 , 12, 12-20, 35	56
902	Impact of medical comorbidity on medication management of schizophrenia. 2007 , 12, 15-7	1
901	Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine. 2007 , 22, 145-52	23
900	The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia. 2007 , 27, 338-43	67
899	Medical comorbidity in bipolar disorder: re-prioritizing unmet needs. 2007 , 20, 406-16	95
898	High prevalence of risk factors for physical illness in a long-stay psychiatric unit. 2007 , 24, 55-58	7
897	Abnormal glucose metabolism in patients treated with antipsychotics. 2007 , 33, 169-75	119
896	The stable patient with schizophrenia--from antipsychotic effectiveness to adherence. 2007 , 17 Suppl 2, S115-22	23
895	A well-being programme in severe mental illness. Reducing risk for physical ill-health: a post-programme service evaluation at 2 years. 2007 , 22, 413-8	78
894	Observance et prise en charge somatique des patients en sant [^] mentale. 2007 , 33, 63-66	1
893	Evidence-based monitoring for metabolic syndrome in clients with chronic schizophrenia. 2007 , 29, 48-56	2
892	Reaching for wellness in schizophrenia. 2007 , 30, 453-79	12

891	Weight Gain Induced by Psychotropic Drugs. 2007 , 3, 165-169		3
890	Conceptual and methodological issues in the design of clinical trials of antipsychotics for the treatment of schizophrenia. 2007 , 21, 699-714		21
889	Cardiovascular effects of antipsychotics. 2007 , 7, 829-39		46
888	Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. 2007 , 32, 289-97		202
887	Management of mental illness in patients with diabetes. 2007 , 34, 713-30, v		3
886	Does antipsychotic polypharmacy increase the risk for metabolic syndrome?. <i>Schizophrenia Research</i> , 2007 , 89, 91-100	3.6	197
885	Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study. <i>Schizophrenia Research</i> , 2007 , 90, 162-73	3.6	157
884	Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis. <i>Schizophrenia Research</i> , 2007 , 93, 90-8	3.6	96
883	Planning for the optimal design of studies to personalize antipsychotic prescriptions in the post-CATIE era: the clinical and pharmacoepidemiological data suggest that pursuing the pharmacogenetics of metabolic syndrome complications (hypertension, diabetes mellitus and hyperlipidemia) may be a reasonable strategy. <i>Schizophrenia Research</i> , 2007 , 96, 185-97	3.6	31
882	A pilot study of a weight management program with food provision in schizophrenia. <i>Schizophrenia Research</i> , 2007 , 96, 198-205	3.6	62
881	Paliperidone: a new extended-release oral atypical antipsychotic. 2007 , 8, 2307-13		20
880	Mental health, antipsychotics and hyperglycaemia. 2007 , 1, 209-224		1
879	Inflammation and schizophrenia. 2007 , 7, 789-96		88
878	The prevalence of metabolic syndrome among psychiatric inpatients in Brazil. 2007 , 29, 330-6		72
877	Associaç�o entre s�ndrome metab�lica e transtornos mentais. 2007 , 34, 28-38		3
876	Cerebro- and cardiovascular conditions in adults with schizophrenia treated with antipsychotic medications. 2007 , 22, 361-4		8
875	Associations of blood homocysteine concentrations in Arab schizophrenic patients. 2007 , 40, 1026-31		28
874	Metabolic syndrome in Thai schizophrenic patients: a naturalistic one-year follow-up study. <i>BMC Psychiatry</i> , 2007 , 7, 14	4.2	36

873	Cardiovascular risks of atypical antipsychotic drug treatment. 2007 , 16, 882-90		52
872	Is rs7566605, a SNP near INSIG2, associated with body mass in a randomized clinical trial of antipsychotics in schizophrenia?. <i>Molecular Psychiatry</i> , 2007 , 12, 321-2	15.1	16
871	Catechol-O-methyltransferase gene regulation in rat frontal cortex. <i>Molecular Psychiatry</i> , 2007 , 12, 322-35.1		11
870	Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials. 2007 , 13, 137-77		61
869	Issues in understanding and treating comorbidity in people with serious mental illness.. 2007 , 14, 70-76		6
868	Physical illness and schizophrenia: a review of the literature. 2007 , 116, 317-33		444
867	Accuracy of body image perception and preferred weight loss strategies in schizophrenia: a controlled pilot study. 2008 , 117, 127-32		6
866	A well-being programme in severe mental illness. Baseline findings in a UK cohort. 2007 , 61, 1971-8		49
865	Atypical antipsychotics related metabolic syndrome in bipolar patients. <i>Journal of Affective Disorders</i> , 2007 , 98, 247-52	6.6	109
864	Gender differences in first episode psychosis. 2008 , 43, 940-6		73
863	Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. 2008 , 200, 317-31		51
862	Olanzapine metabolic side effects: a weight gain issue?. 2008 , 3, 237-40		2
861	Weight management in a cohort of Irish inpatients with serious mental illness (SMI) using a modular behavioural programme. A preliminary service evaluation. <i>BMC Psychiatry</i> , 2008 , 8, 76	4.2	13
860	Relative risk of diabetes, dyslipidaemia, hypertension and the metabolic syndrome in people with severe mental illnesses: systematic review and metaanalysis. <i>BMC Psychiatry</i> , 2008 , 8, 84	4.2	134
859	Supporting the lifestyle modification and treatment of type 2 diabetes for people with severe mental illness. 2008 , 5, 58-63		3
858	Gene expression on liver toxicity induced by administration of haloperidol in rats with severe fatty liver. 2008 , 10, 177-84		16
857	Treating pediatric patients with antipsychotic drugs: balancing benefits and safety. 2008 , 75, 276-86		5
856	Screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics: a quality improvement programme. 2008 , 118, 26-33		54

855	Antipsychotic use in the elderly: what doctors say they do, and what they do. 2008 , 27, 134-42		6
854	Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. <i>Molecular Psychiatry</i> , 2008 , 13, 27-35	15.1	467
853	Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder. 2008 , 10, 342-8		144
852	Metabolic syndrome in bipolar disorder: a cross-sectional assessment of a Health Management Organization database. 2008 , 10, 607-16		97
851	Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. 2008 , 10, 788-97		120
850	Modal subcomponents of metabolic syndrome in patients with bipolar disorder. <i>Journal of Affective Disorders</i> , 2008 , 106, 91-7	6.6	64
849	Increased rates of obesity in first-presentation adults with mood disorders over the course of four-year follow-up. <i>Journal of Affective Disorders</i> , 2008 , 109, 127-31	6.6	12
848	Paliperidone for schizophrenia. 2008 , 65, 403-13		43
847	Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants. <i>Schizophrenia Research</i> , 2008 , 98, 47-54	3.6	80
846	Concordance of standard and modified NCEP ATP III criteria for identification of metabolic syndrome in outpatients with schizophrenia treated with antipsychotics: a corollary from the CLAMORS study. <i>Schizophrenia Research</i> , 2008 , 99, 23-8	3.6	18
845	Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin. <i>Schizophrenia Research</i> , 2008 , 100, 70-85	3.6	111
844	Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. <i>Schizophrenia Research</i> , 2008 , 101, 273-86	3.6	222
843	Metabolic syndrome in first episode schizophrenia - a randomized double-blind controlled, short-term prospective study. <i>Schizophrenia Research</i> , 2008 , 101, 266-72	3.6	90
842	Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. <i>Schizophrenia Research</i> , 2008 , 101, 295-303	3.6	188
841	Use of medications to reduce cardiovascular risk among individuals with psychotic disorders and Type 2 diabetes. <i>Schizophrenia Research</i> , 2008 , 101, 256-65	3.6	15
840	Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. <i>Schizophrenia Research</i> , 2008 , 103, 104-9	3.6	59
839	A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: findings from the CLAMORS study. <i>Schizophrenia Research</i> , 2008 , 104, 1-12	3.6	62
838	Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. <i>Schizophrenia Research</i> , 2008 , 105, 175-87	3.6	179

837	Changes in non-high-density lipoprotein cholesterol levels and triglyceride/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine. <i>Schizophrenia Research</i> , 2008 , 106, 300-7	3.6	19
836	Antipsicóticos atípicos: un factor de riesgo de síndrome metabólico. 2008 , 55, 61-63		
835	Handbook of Behavioral and Cognitive Therapies with Older Adults. 2008 ,		14
834	Antipsychotic Medication-Induced Weight Gain and Risk for Diabetes and Cardiovascular Disease. 2007 , 223-245		1
833	[Drug treatment of early-onset schizophrenia]. 2008 , 37, 853-8		0
832	Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine. 2008 , 32, 925-31		35
831	Pharmacogenetic testing in psychiatry: a review of features and clinical realities. 2008 , 28, 599-617		62
830	Evidence of exacerbated cognitive deficits in schizophrenia patients with comorbid diabetes. 2008 , 49, 123-31		42
829	Management of physical health in schizophrenia: a stepping stone to treatment success. 2008 , 18 Suppl 2, S121-8		20
828	Overcoming hurdles to achieving good physical health in patients treated with atypical antipsychotics. 2008 , 18 Suppl 2, S102-7		5
827	Metabolic syndrome in outpatients receiving antipsychotic therapy in routine clinical practice: a cross-sectional assessment of a primary health care database. 2008 , 23, 100-8		42
826	Traitements neuroleptiques et troubles métaboliques. 2008 , 2, 593-599		4
825	Transforming mental health care: realities, priorities, and prospects. 2008 , 31, 1-9		6
824	Best Practices For Co-Occurring Disorders: Medical Co-Management of Psychiatric Patients-Addressing the "Other" Dual Diagnoses. 2008 , 4, 420-425		4
823	Admission to a psychiatric unit and changes in tobacco smoking. 2008 , 4, 12		5
822	Safety monitoring of patients on atypical antipsychotics. 2008 , 17, 469-72		6
821	Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone. 2008 , 33, 985-94		61
820	A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. 2008 , 69, 1046-56		89

819	What explains the diffusion of treatments for mental illness?. 2008 , 165, 1385-92		24
818	Recently patented agents with possible antipsychotic indication. 2008 , 18, 1327-1332		
817	Schizophrenia, obesity, and antipsychotic medications: what can we do?. 2008 , 120, 18-33		51
816	Waist circumference does not predict insulin resistance in African American schizophrenia patients. 2008 , 1, 93-104		0
815	Desvenlafaxine succinate for the treatment of major depressive disorder. 2008 , 9, 2129-36		5
814	High bone turnover but normal bone mineral density in women suffering from schizophrenia. <i>Psychological Medicine</i> , 2008 , 38, 1195-201	6.9	25
813	Data to Manage the Mortality Crisis. 2008 , 37, 49-68		14
812	Schizophrenia Host Vulnerability and Risk of Metabolic Disturbances During Treatment with Antipsychotics. 2008 , 6, 172-179		0
811	Medication-Induced Weight Gain and Dyslipidemia in Patients With Schizophrenia. 2008 , 6, 246-253		
810	The urgent need for monitoring and intervention to reduce metabolic risk factors in patients with schizophrenia. 2008 , 13, 5-6		1
809	Prevalence of metabolic syndrome among inpatients with schizophrenia. 2008 , 38, 103-12		36
808	D2 receptor partial agonists: treatment of CNS disorders of dopamine function. 2008 , 8, 1068-88		18
807	Bibliography Schizophrenia. 2008 , 6, 197-199		
806	Clinical trial of wellness training: health promotion for severely mentally ill adults. 2008 , 196, 475-83		33
805	Factor relationships of metabolic syndrome and echocardiographic phenotypes in the HyperGEN study. 2008 , 26, 1360-6		11
804	Addressing cardiometabolic risk during treatment with antipsychotic medications. 2008 , 21, 613-8		22
803	Efficacy of lipid-lowering medications in patients treated with clozapine: a naturalistic study. 2008 , 28, 348-9		9
802	Implications of CATIE for mental health services researchers. 2008 , 59, 526-9		7

801	La prescription de psychotropes chez l'adolescent hospitalis�. 2008 , 84, 645	
800	An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia. 2008 , 4, 967-76	11
799	[Brazilian Consensus on second-generation antipsychotics and metabolic disorders]. 2008 , 30, 77-85	15
798	Effects of risperidone and olanzapine on remnant-like lipoprotein particle cholesterol (RLP-C) in schizophrenic patients. 2008 , 4, 481-6	3
797	Psychiatric disorders and general medical conditions: implications for the clinician. 2008 , 11, 18-22	2
796	Initial assessment and initial pharmacological treatment in the acute phase. 177-200	1
795	Screening for and monitoring of cardio-metabolic risk factors in outpatients with severe mental illness in a primary care setting. 2009 , 12, 287-92	3
794	Alteraciones metab�licas asociadas al uso de terapia antipsic�tica. 2009 , 137,	2
793	Improvement of metabolic risk profile under second-generation antipsychotics: a pilot intervention study. 2009 , 54, 275-9	13
792	Glucose dysregulation among veterans living with schizophrenia-related disorders after switching second-generation antipsychotics. 2009 , 49, 223-31	2
791	Prevalence of metabolic syndrome among Australians with severe mental illness. 2009 , 190, 176-9	88
790	Kraepelin's dichotomy is true: contrasting brain dysfunction at the extremes of human growth and maturation. Excitability, the fundamental property of nervous tissue, is affected. 2009 , 10, 998-1015	6
789	Metabolic profile of antipsychotic-naive individuals with non-affective psychosis. 2009 , 194, 434-8	193
788	Metabolic risk factors among medicaid outpatients with schizophrenia receiving second-generation antipsychotics. 2009 , 60, 1686-9	37
787	Pharmacogenomics: the promise of personalized medicine for CNS disorders. 2009 , 34, 159-72	65
786	A link between schizophrenia and diabetes?: Insights from the pre-antipsychotic era. 2009 , 21, 139-145	
785	Abstracts from the XI Swedish Heart Association, April 22-24, 2009, Uppsala, Sweden. 2009 , 57, 3-38	
784	Body composition in psychotic disorders: a general population survey. <i>Psychological Medicine</i> , 2009 , 39, 801-10	6.9 51

783	What do persons with mental illnesses need to quit smoking? Mental health consumer and provider perspectives. 2009 , 32, 276-84	43
782	Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes. 2009 , 32, 1037-42	133
781	Metabolic and Cardiac Side Effects of Second-generation Antipsychotics: What Every Clinician Should Know. 2009 , 22, 478-488	8
780	Cardiovascular effects of noncardiovascular drugs. 2009 , 120, 1123-32	17
779	Prevalence of metabolic syndrome among an Iranian cohort of inpatients with schizophrenia. 2009 , 39, 451-62	18
778	Systemic hypotheses for generalized cognitive deficits in schizophrenia: a new take on an old problem. 2009 , 35, 403-14	110
777	Creation of a metabolic monitoring program for second-generation (atypical) antipsychotics. 2009 , 15, 292-301	6
776	Metabolic syndrome in female patients with schizophrenia treated with second generation antipsychotics: a 3-month follow-up. 2009 , 23, 915-22	14
775	Health care for patients with serious mental illness: family medicine's role. 2009 , 22, 187-95	59
774	Effects of nutritional intervention on body weight and body composition of obese psychiatric patients taking olanzapine. 2009 , 25, 729-35	21
773	Metabolic syndrome and associated cardiovascular risk factors in the treatment of persons with human immunodeficiency virus and severe mental illness. 2009 , 124, 269-78	14
772	The incidence of metabolic syndrome and its reversal in a cohort of schizophrenic patients followed for one year. 2009 , 43, 1106-11	38
771	Assessment of a point-of-care metabolic risk screening program in outpatients receiving antipsychotic agents. 2009 , 29, 975-87	30
770	When the heart and the mind collide: cardiovascular risk factors and antipsychotic use in the schizophrenic population. 2009 , 4, 1-5	2
769	Commentary: genome-based CNS drug discovery: D-amino acid oxidase (DAAO) as a novel target for antipsychotic medications: progress and challenges. 2009 , 78, 1360-5	25
768	UK cost-consequence analysis of aripiprazole in schizophrenia: diabetes and coronary heart disease risk projections (STAR study). 2009 , 259, 239-47	16
767	Prevalence and predictors of metabolic syndrome among patients attending an outpatient clozapine clinic in Australia. 2009 , 23, 261-8	37
766	Metabolic syndrome and major depressive disorder: co-occurrence and pathophysiologic overlap. 2009 , 9, 51-9	99

765	Metabolic risks in older adults receiving second-generation antipsychotic medication. 2009 , 11, 33-40		18
764	WAY-163909, a 5-HT _{2C} agonist, enhances the preclinical potency of current antipsychotics. 2009 , 204, 37-48		23
763	Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration. <i>BMC Psychiatry</i> , 2009 , 9, 80	4.2	19
762	The development of the serious mental illness physical Health Improvement Profile. 2009 , 16, 493-8		58
761	Metabolic syndrome: a picture of health?. 2009 , 21, 197-199		1
760	Schizophrenia and physical health problems. 2009 , 119, 15-21		175
759	The metabolic syndrome and schizophrenia. 2009 , 119, 4-14		193
758	Low-fat oxidation may be a factor in obesity among men with schizophrenia. 2009 , 119, 451-6		10
757	Prevalence of metabolic syndrome among patients with schizophrenia or schizoaffective disorder in Taiwan. 2009 , 120, 274-80		74
756	Obesity, serious mental illness and antipsychotic drugs. 2009 , 11, 665-79		90
755	Obesity among those with mental disorders: a National Institute of Mental Health meeting report. 2009 , 36, 341-50		281
754	Schizophr�nie et vieillissement : aspects cliniques. 2009 , 167, 380-384		1
753	Changes in metabolic syndrome parameters in patients with schizoaffective disorder who participated in a randomized, placebo-controlled trial of topiramate. 2009 , 2, 106-11		4
752	Clinical monitoring and management of the metabolic syndrome in patients receiving atypical antipsychotic medications. 2009 , 3, 5-15		58
751	Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study. <i>Schizophrenia Research</i> , 2009 , 110, 80-9	3.6	26
750	Association of adiponectin and metabolic syndrome among patients taking atypical antipsychotics for schizophrenia: a cohort study. <i>Schizophrenia Research</i> , 2009 , 111, 1-8	3.6	61
749	Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study. <i>Schizophrenia Research</i> , 2009 , 111, 9-16	3.6	128
748	Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study. <i>Schizophrenia Research</i> , 2009 , 113, 112-21	3.6	29

747	Schizophrenia and the incidence of cardiovascular morbidity: a population-based longitudinal study in Ontario, Canada. <i>Schizophrenia Research</i> , 2009 , 115, 325-32	3.6	27
746	Metabolic syndrome in people with schizophrenia: a review. 2009 , 8, 15-22		383
745	The treatment of borderline personality disorder: implications of research on diagnosis, etiology, and outcome. 2009 , 5, 277-90		49
744	Sex-specific differences in side effects of psychotropic drugs: genes or gender?. 2009 , 10, 1511-26		65
743	Clozapine Use in HIV-Infected Schizophrenia Patients: A Case-Based Discussion and Review. 2009 , 50, 626-632		11
742	Prevalence and awareness of cardiovascular risk factors in patients with schizophrenia: a cross-sectional study in a low cardiovascular disease risk geographical area. 2009 , 24, 431-41		41
741	Management of schizophrenia with obesity, metabolic, and endocrinological disorders. 2009 , 32, 775-94		36
740	Metabolic risk status and second-generation antipsychotic drug selection: a retrospective study of commercially insured patients. 2009 , 29, 26-32		28
739	Association of posttraumatic stress disorder with increased prevalence of metabolic syndrome. 2009 , 29, 210-5		47
738	Prevalence of metabolic syndrome in patients with psychotic disorders in the Netherlands. 2009 , 29, 399-402		11
737	Improved body weight and metabolic outcomes in overweight or obese psychiatric patients switched to amisulpride from other atypical antipsychotics. 2009 , 29, 529-36		16
736	Waist circumference is the best anthropometric predictor for insulin resistance in nondiabetic patients with schizophrenia treated with clozapine but not olanzapine. 2009 , 15, 251-61		15
735	HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study. 2009 , 29, 16-20		68
734	Clinical antipsychotic trials of intervention effectiveness study: a pragmatic trial?. 2009 , 29, 410-1		
733	Metabolic Syndrome in Psychiatric Inpatients Treated for Depression. 2009 , 90-104		2
732	Glucose Abnormalities in Schizophrenia, Bipolar and Major Depressive Disorders. 2009 , 47-65		3
731	Obesity and Mental Illness. 2009 , 25-46		10
730	Lipid profile screening in second-generation antipsychotic users: the gap between policy and practice. 2010 , 5, 299-303		

729	Association between the 1291-C/G polymorphism in the adrenergic α_2 receptor and the metabolic syndrome. 2010 , 30, 667-71	13
728	Antipsychotic therapy: risks and benefits at end of life. 2010 , 18, 157-162	
727	Metabolic syndrome with the atypical antipsychotics. 2010 , 17, 460-6	123
726	The adjunctive use of metformin to treat or prevent atypical antipsychotic-induced weight gain: a review. 2010 , 16, 289-96	12
725	Cardiovascular aspects of antipsychotics. 2010 , 23, 574-81	58
724	Plasma orexin A, ghrelin, cholecystokinin, visfatin, leptin and agouti-related protein levels during 6-week olanzapine treatment in first-episode male patients with psychosis. 2010 , 25, 165-71	24
723	Adults with mood disorders have an increased risk profile for cardiovascular disease within the first 2 years of treatment. 2010 , 55, 362-8	21
722	Bipolar Disorder and Safety Monitoring for Clinicians: A Review of the Evidence and the Implications. 2010 , 367-383	
721	Introduction and Overview of the Real World Management of Schizophrenia in the Comorbid Patient. 2010 , 15, 3-5	
720	Cancer et schizophr�nie : donn�es �pidemiologiques et hypoth�ses �tiopathog�niques. 2010 , 4, 7-11	1
719	Trends in adult antipsychotic polypharmacy: progress and challenges in Florida's Medicaid program. 2010 , 46, 523-30	17
718	Impact of a nurse-led intervention to improve screening for cardiovascular risk factors in people with severe mental illnesses. Phase-two cluster randomised feasibility trial of community mental health teams. 2010 , 10, 61	58
717	Using the serious mental illness health improvement profile [HIP] to identify physical problems in a cohort of community patients: a pragmatic case series evaluation. 2010 , 47, 136-45	59
716	Bipolar disorder and metabolic syndrome: an international perspective. <i>Journal of Affective Disorders</i> , 2010 , 126, 366-87	6.6 153
715	Diabetes and cardiovascular risk in severe mental illness: a missed opportunity and challenge for the future. 2010 , 27, 79-84ii	24
714	Comparison of the metabolic and economic consequences of long-term treatment of schizophrenia using ziprasidone, olanzapine, quetiapine and risperidone in Canada: a cost-effectiveness analysis. 2010 , 16, 744-55	21
713	Rethinking schizophrenia. 2010 , 468, 187-93	1163
712	Targeted Care Plans for Schizophrenia. 2010 , 15, 6-9	

711	Metabolic side effects and risk of cardiovascular disease. 173-188		
710	Psychotic Patients. 2010 , 119-132		
709	Abnormal laboratory values during the acute and recovery phases in schizophrenic patients: a retrospective study. 2010 , 6, 281-8		8
708	Safety and tolerability of antipsychotics: focus on amisulpride. 2010 , 2, 205-11		22
707	Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study. 2010 , 71, 304-11		68
706	Antipsychotics and metabolics in the post-CATIE era. 2010 , 4, 23-42		26
705	A randomised controlled study of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced acute dystonia or parkinsonism. 2010 , 24, 91-8		20
704	Comparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and quetiapine in schizophrenia. 2010 , 24, 1001-9		20
703	The prevalence of undiagnosed metabolic abnormalities in people with serious mental illness. 2010 , 24, 867-73		52
702	The physical health challenges in patients with severe mental illness: cardiovascular and metabolic risks. 2010 , 24, 1-8		10
701	Specialty care medical homes for people with severe, persistent mental disorders. 2010 , 29, 867-73		98
700	Weight gain in antipsychotic-naive patients: a review and meta-analysis. <i>Psychological Medicine</i> , 2010 , 40, 187-200	6.9	81
699	The effects of hypertension and body mass index on cognition in schizophrenia. 2010 , 167, 1232-9		61
698	Linkage of cognitive impairments with metabolic disorders in schizophrenia. 2010 , 167, 1155-7		12
697	Psychodynamic aspects of psychopharmacology. 2010 , 38, 655-74		6
696	Gender differences in antipsychotic prescribing. 2010 , 22, 472-84		50
695	The prevalence and predictive value of individual criteria for metabolic syndrome in schizophrenia: a Northern Finland 1966 Birth Cohort Study. 2010 , 11, 262-7		14
694	World Congress on the Insulin Resistance Syndrome, 2009: Insulin resistance mechanisms, the brain, and insulin resistance in youth and in the polycystic ovary syndrome. 2010 , 33, e124-e130		78

693	Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. 2010 , 67, 17-24		159
692	Medical illnesses in people with schizophrenia. 2010 , 45, 591-611, vi		2
691	Prevalence of cardiovascular risk factors and disease in people with schizophrenia: a population-based study. <i>Schizophrenia Research</i> , 2010 , 117, 75-82	3.6	134
690	Higher white blood cell counts are associated with an increased risk for metabolic syndrome and more severe psychopathology in non-diabetic patients with schizophrenia. <i>Schizophrenia Research</i> , 2010 , 118, 211-7	3.6	60
689	Prevalence of metabolic syndrome among patients with schizophrenia in Japan. <i>Schizophrenia Research</i> , 2010 , 123, 244-50	3.6	63
688	Phenotypic characteristics in metabolically obese but normal weight non-diabetic patients with schizophrenia. <i>Schizophrenia Research</i> , 2010 , 124, 49-53	3.6	6
687	Physical health in schizophrenia: a challenge for antipsychotic therapy. 2010 , 25 Suppl 2, S6-11		43
686	Physical health management in psychiatric settings. 2010 , 25 Suppl 2, S22-8		45
685	Clozapine and cardiometabolic health in chronic schizophrenia: correlations and consequences in a clinical context. 2010 , 18, 32-41		11
684	Review: A systematic review of hypothalamic-pituitary-adrenal axis function in schizophrenia: implications for mortality. 2010 , 24, 91-118		209
683	The time-dependent change of insulin secretion in schizophrenic patients treated with olanzapine. 2010 , 34, 866-70		38
682	Insulin resistance and metabolic profile in antipsychotic naïve schizophrenia patients. 2010 , 34, 1202-7		38
681	Patients taking medications for bipolar disorder are more prone to metabolic syndrome than Korea's general population. 2010 , 34, 1243-9		26
680	Coronary heart disease and cardiac conduction abnormalities in persons with psychotic disorders in a general population. <i>Psychiatry Research</i> , 2010 , 175, 126-32	9.9	16
679	Obesity and smoking in patients with schizophrenia and normal controls: a case-control study. <i>Psychiatry Research</i> , 2010 , 176, 13-6	9.9	16
678	Antipsychotic medication, mortality and neurodegeneration: The need for more selective use and lower doses. 2010 , 2, 50-69		13
677	Sindrome metabolica, disturbi dello spettro schizofrenico e trattamenti. Risultati di uno studio naturalistico. 2010 , 29, 110-115		1
676	Management of antipsychotic-related weight gain. 2010 , 10, 1175-200		77

675	Association between HTR2C polymorphisms and metabolic syndrome in patients with schizophrenia treated with atypical antipsychotics. <i>Schizophrenia Research</i> , 2011 , 125, 179-86	3.6	29
674	Prevention of metabolic syndrome in serious mental illness. 2011 , 34, 109-25		15
673	At-risk variant in TCF7L2 for type II diabetes increases risk of schizophrenia. 2011 , 70, 59-63		101
672	Atypical antipsychotic-induced weight gain: insights into mechanisms of action. 2011 , 25, 1035-59		108
671	Schizophrenia and Medical Illness: Is Medical Illness the Consequence of Schizophrenia or Its Treatment?. 2011 , 267-287		
670	American Diabetes Association Postgraduate Meetings--2011. 2011 , 34, e164-9		2
669	The metabolic syndrome and its constituting variables in atypical antipsychotic-treated subjects: comparison with other drug treatments, drug-free psychiatric patients, first-degree relatives and the general population in Venezuela. <i>Schizophrenia Research</i> , 2011 , 126, 93-102	3.6	30
668	Increased Framingham 10-year risk of coronary heart disease in middle-aged and older patients with psychotic symptoms. <i>Schizophrenia Research</i> , 2011 , 125, 295-9	3.6	46
667	Schizophrenia patients at higher risk of diabetes, hypertension and hyperlipidemia: a population-based study. <i>Schizophrenia Research</i> , 2011 , 126, 110-6	3.6	57
666	Cross-sectional prevalence of metabolic syndrome in Korean patients with schizophrenia. <i>Schizophrenia Research</i> , 2011 , 128, 179-81	3.6	10
665	Dietary, lifestyle and pharmacogenetic factors associated with arteriole endothelial-dependent vasodilatation in schizophrenia patients treated with atypical antipsychotics (AAPs). <i>Schizophrenia Research</i> , 2011 , 130, 20-6	3.6	30
664	Analysis of efficacy and side effects in CATIE demonstrates drug response subgroups and potential for personalized medicine. <i>Schizophrenia Research</i> , 2011 , 132, 114-20	3.6	17
663	Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder. 2011 , 31, 455-82		74
662	Translating potential biomarker candidates for schizophrenia and depression to animal models of psychiatric disorders. 2011 , 11, 721-33		11
661	A pilot study of antipsychotic prescribing decisions for acutely-ill hospitalized patients. 2011 , 35, 246-51		3
660	The prevalence of metabolic syndrome in Korean patients with schizophrenia receiving a monotherapy with aripiprazole, olanzapine or risperidone. 2011 , 35, 1273-8		23
659	Association of plasma retinol-binding protein-4, adiponectin, and high molecular weight adiponectin with metabolic adversities in patients with schizophrenia. 2011 , 35, 1927-32		11
658	Change in psychiatrists' attitudes towards the physical health care of patients with schizophrenia coinciding with the dissemination of the consensus on physical health in patients with schizophrenia. 2011 , 26, 305-12		15

- 657 Diabetes, cardiovascular disease, and health care use in people with and without schizophrenia. **2011**, 26, 327-32 12
- 656 The Impact of Cardiometabolic Risk in Patients with Severe Mental Illness: From Evidence to Clinical Management. **2011**,
- 655 Specific mechanism of action of amisulpride in the treatment of schizophrenia and correlation with clinical response and tolerability. **2011**, 49
- 654 Síndrome metabólico y antipsicóticos de segunda generación. **2011**, 31, 303-320 4
- 653 Heart rate variability and metabolic syndrome in hospitalized patients with schizophrenia. **2011**, 41, 788-94 11
- 652 Monitoring and prevalence rates of metabolic syndrome in military veterans with serious mental illness. **2011**, 6, e19298 27
- 651 Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study. **2011**, 31, 86-91 44
- 650 Factors in second-generation antipsychotic switching patterns in a national sample of older veterans with schizophrenia. **2011**, 62, 47-53 19
- 649 The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs. **2011**, 26, 291-302 45
- 648 Association between the ROBO1 gene and body mass index in patients using antipsychotics. **2011**, 21, 202-7 7
- 647 Revascularisation and mortality rates following acute coronary syndromes in people with severe mental illness: comparative meta-analysis. **2011**, 198, 434-41 72
- 646 Incidence of diabetes in patients with schizophrenia: a population-based study. **2011**, 56, 19-26 18
- 645 Beyond the facts in schizophrenia: closing the gaps in diagnosis, pathophysiology, and treatment. **2011**, 20, 317-27 39
- 644 Schizophrenia: medical illness, mortality, and aging. **2011**, 41, 245-51 43
- 643 Prevalence of obesity and metabolic syndrome in a long-stay psychiatric unit. **2011**, 28, 205-208 1
- 642 [Comorbidity of metabolic syndrome, diabetes and schizophrenia: theoretical and practical considerations]. **2011**, 152, 505-11 4
- 641 Schizophrenia: The Epidemiological Horizon. **2011**, 185-225 5
- 640 Ziprasidone hydrochloride: what role in the management of schizophrenia?. **2011**, 3, 1-16 11

639	Weight gain associated with taking psychotropic medication: an integrative review. 2011 , 20, 202-22		71
638	Description of a healthy lifestyle intervention for people with serious mental illness taking second-generation antipsychotics. 2011 , 20, 428-37		50
637	A role for mental health nursing in the physical health care of consumers with severe mental illness. 2011 , 18, 706-11		40
636	Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder. 2011 , 124, 214-25		31
635	Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs. <i>Molecular Psychiatry</i> , 2011 , 16, 321-32	15.1	123
634	Association study of MDR1 and 5-HT2C genetic polymorphisms and antipsychotic-induced metabolic disturbances in female patients with schizophrenia. 2011 , 11, 35-44		35
633	Gender-specific lipid profiles in patients with bipolar disorder. 2011 , 45, 1036-41		11
632	Reduced peak oxygen uptake and implications for cardiovascular health and quality of life in patients with schizophrenia. <i>BMC Psychiatry</i> , 2011 , 11, 188	4.2	18
631	[Detection of cardiovascular risk factors in patients with psychosis]. 2011 , 43, 386-7		2
630	The prevalence and clinical correlates of metabolic syndrome in patients with schizophrenia: findings from a cohort in Turkey. 2011 , 261, 69-78		28
629	Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study. <i>BMC Psychiatry</i> , 2011 , 11, 118	4.2	55
628	Prevalence of metabolic syndrome in patients with schizophrenia, and metabolic changes after 3 months of treatment with antipsychotics--results from a German observational study. <i>BMC Psychiatry</i> , 2011 , 11, 173	4.2	22
627	The serious mental illness health improvement profile [HIP]: study protocol for a cluster randomised controlled trial. 2011 , 12, 167		17
626	Collaborative planning approach to inform the implementation of a healthcare manager intervention for Hispanics with serious mental illness: a study protocol. 2011 , 6, 80		22
625	Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. 2011 , 10, 52-77		1288
624	Polymorphisms of INSIG2, MC4R, and LEP are associated with obesity- and metabolic-related traits in schizophrenic patients. 2011 , 31, 705-11		24
623	Prevalence of metabolic syndrome in patients with schizophrenia. 2011 , 18, 109-117		11
622	Prevalence of the metabolic syndrome in Danish psychiatric outpatients treated with antipsychotics. 2011 , 65, 345-52		30

621	Bipolar Hastalarda Serum Ghrelin Seviyeleri ve Metabolik Sendrom Arasındaki İlişki. 2011 , 48, 1-1	1
620	Symposiums. 2011 , 45, A5-A25	
619	The high prevalence of poor physical health and unhealthy lifestyle behaviours in individuals with severe mental illness. 2011 , 32, 589-97	267
618	Cardiovascular risk in patients admitted for psychosis compared with findings from a population-based study. 2011 , 65, 192-202	7
617	Unmet treatment needs in schizophrenia patients: is aripiprazole a potential therapeutic option?. 2011 , 11, 989-1006	4
616	Metabolic syndrome and psychiatrists' choice of follow-up interventions in patients treated with atypical antipsychotics in Denmark and Sweden. 2011 , 65, 40-6	10
615	Safety of antipsychotics in people with intellectual disability. 2011 , 199, 289-95	31
614	Psychological Co-morbidities of Physical Illness. 2011 ,	10
613	Relationship between cumulative BMI and symptomatic, psychosocial, and medical outcomes in patients with borderline personality disorder. 2011 , 25, 421-31	20
612	Schizophrenia Is a Misdiagnosis. 2012 ,	8
611	Metabolic syndrome in schizophrenia: a comparative study of antipsychotic-free/naïve and antipsychotic-treated patients from India. 2012 , 66, 215-21	23
610	Metabolic syndrome in patients with severe mental illness undergoing psychiatric rehabilitation receiving high dose antipsychotic medication. 2012 , 34, 247-54	1
609	The relationship between serum uric acid concentration and metabolic syndrome in patients with schizophrenia or schizoaffective disorder. 2012 , 32, 585-92	11
608	Risk factors associated with metabolic syndrome in bipolar and schizophrenia subjects treated with antipsychotics: the role of folate pharmacogenetics. 2012 , 32, 261-5	71
607	Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: a prospective, randomized, controlled trial. 2012 , 32, 449-57	26
606	Atypical antipsychotic drugs, schizophrenia, and metabolic syndrome in non-Euro-American societies. 2012 , 35, 141-7	33
605	Cardiometabolic risk factors in people with psychotic disorders: the second Australian survey of psychosis: going back to the foundations. 2012 , 46, 901-3	3
604	Interviewer-perceived honesty as a mediator of racial disparities in the diagnosis of schizophrenia. 2012 , 63, 875-80	35

603	DNA methylation in schizophrenia subjects: gender and MTHFR 677C/T genotype differences. 2012 , 4, 261-8		36
602	Polyunsaturated fatty acids in emerging psychosis. 2012 , 18, 576-91		15
601	Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics: a replication study. 2012 , 12, 62-7		38
600	Inhibition of mouse brown adipocyte differentiation by second-generation antipsychotics. 2012 , 44, 545-53		20
599	Cardiometabolic risk factors in people with psychotic disorders: the second Australian national survey of psychosis. 2012 , 46, 753-61		152
598	Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. <i>Psychological Medicine</i> , 2012 , 42, 125-47	6.9	240
597	Obesity and weight-related medical problems of incarcerated persons with and without mental disorders. 2012 , 18, 219-32		10
596	An update on lipid profile screening in second-generation antipsychotic users in the USA. 2012 , 7, 509-523		
595	Special biological issues in the management of women with schizophrenia. 2012 , 12, 823-33		8
594	Comparison of long-term (at least 24 weeks) weight gain and metabolic changes between adolescents and adults treated with olanzapine. 2012 , 22, 157-65		31
593	Cardiovascular morbidity, mortality and pharmacotherapy in patients with schizophrenia. <i>Psychological Medicine</i> , 2012 , 42, 2275-85	6.9	72
592	Medication for psychosis--consumption and consequences: the second Australian national survey of psychosis. 2012 , 46, 762-73		44
591	Gender differences in schizophrenia and first-episode psychosis: a comprehensive literature review. 2012 , 2012, 916198		304
590	Insulin secretion and sensitivity after single-dose amisulpride, olanzapine or placebo in young male subjects: double blind, cross-over glucose clamp study. 2012 , 45, 223-8		9
589	Health management of older persons with chronically medicated psychotic disorders: the results of a survey in France. 2012 , 24, 496-502		8
588	Metabolic monitoring training program implementation in the community setting was associated with improved monitoring in second-generation antipsychotic-treated children. 2012 , 57, 292-9		21
587	Let's get physical: improving the medical care of people with severe mental illness. 2012 , 18, 216-225		9
586	Managing Medication Effects on Body Weight: Do Behavioral Interventions Work?. 2012 , 10, 130-139		

585 Bibliography: Schizophrenia. **2012**, 10, 186-188

584	High mortality and low access to care following incident acute myocardial infarction in individuals with schizophrenia. <i>Schizophrenia Research</i> , 2012 , 142, 52-7	3.6	32
583	Relationship between metabolic syndrome and cognition in patients with schizophrenia. <i>Schizophrenia Research</i> , 2012 , 142, 171-6	3.6	65
582	Schizophrenia for primary care providers: how to contribute to the care of a vulnerable patient population. 2012 , 125, 223-30		26
581	Ziprasidone with adjunctive mood stabilizer in the maintenance treatment of bipolar I disorder: long-term changes in weight and metabolic profiles. 2012 , 22, 123-31		15
580	Cardiovascular and metabolic risk in outpatients with schizoaffective disorder treated with antipsychotics: results from the CLAMORS study. 2012 , 27, 267-74		15
579	Measurement of waist circumference at different sites affects the detection of abdominal obesity and metabolic syndrome among psychiatric patients. <i>Psychiatry Research</i> , 2012 , 197, 322-6	9.9	10
578	Abnormality of glycometabolism related factors in non-psychotic offspring of schizophrenic patients. <i>Psychiatry Research</i> , 2012 , 198, 183-6	9.9	15
577	Prevalence of metabolic syndrome in patients with schizophrenia in India. <i>Psychiatry Research</i> , 2012 , 200, 1035-7	9.9	28
576	Pharmacological treatment of schizophrenia. 2012 , 24, 489-98		7
575	Comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia: a 12-month, prospective, open-label study. 2012 , 26, 1201-10		23
574	Hospital admissions and pharmacotherapy before out-of-hospital cardiac arrest according to age. 2012 , 83, 584-90		10
573	Validation of candidate genes associated with cardiovascular risk factors in psychiatric patients. 2012 , 36, 213-9		2
572	Overweight and obesity in patients with bipolar disorder or schizophrenia compared with a non-psychiatric sample. 2012 , 37, 169-75		49
571	Cognitive deficits, obesity and disability in schizophrenia. 2012 , 3,		8
570	Metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-naïve schizophrenia patients after treatment with risperidone. 2012 , 11, 4338-50		74
569	Psychometric properties of the Spanish version of the Body Weight, Image and Self-Esteem Evaluation Questionnaire in patients with severe mental disorders. 2012 , 53, 1237-42		3
568	The lipid profiles in Japanese patients with schizophrenia treated with antipsychotic agents. 2012 , 34, 525-8		10

567	Post-myocardial-infarction quality of care among disabled Medicaid beneficiaries with and without serious mental illness. 2012 , 34, 493-9		3
566	Screening for obstructive sleep apnea among individuals with severe mental illness at a primary care clinic. 2012 , 34, 660-4		32
565	Relationship between inflammation and metabolic syndrome following treatment with paliperidone for schizophrenia. 2012 , 39, 295-300		11
564	Functional impairment in people with schizophrenia: focus on employability and eligibility for disability compensation. <i>Schizophrenia Research</i> , 2012 , 140, 1-8	3.6	99
563	Schizophrenia Spectrum Conditions. 2012 ,		
562	Current Schizophrenia. 2012 ,		0
561	Schizophrenia in women and children: a selective review of literature from developing countries. 2012 , 24, 467-82		8
560	Prevalence of metabolic syndrome among patients with schizophrenia in Palestine. <i>BMC Psychiatry</i> , 2012 , 12, 235	4.2	29
559	Recent advances in understanding and mitigating adipogenic and metabolic effects of antipsychotic drugs. <i>Frontiers in Psychiatry</i> , 2012 , 3, 62	5	19
558	Obesity in pregnancy and mental health. 70-80		1
557	Commentary. 2012 , 03, 284-285		
556	Prevalence of the Metabolic Syndrome among Outpatients with Schizophrenia or Schizoaffective Disorder. 2012 , 15, 39		1
555	Medical writing for CNS indications. 156-168		
554	Association between the GIPR gene and the insulin level after glucose loading in schizophrenia patients treated with olanzapine. 2012 , 12, 507-12		8
553	Predictors of death from natural causes in schizophrenia: 10-year follow-up of a community cohort. 2012 , 47, 843-7		14
552	Hyperlipidemia in patients with schizophrenia: a national population-based study. 2012 , 34, 360-7		11
551	Eight-year trends of cardiometabolic morbidity and mortality in patients with schizophrenia. 2012 , 34, 368-79		31
550	Prevalence of baseline lipid monitoring in patients prescribed second-generation antipsychotics during their index hospitalization: a retrospective cohort study. 2012 , 34, 380-4		5

549	Metabolic syndrome in antipsychotic naïve patients diagnosed with schizophrenia. 2012 , 6, 326-31		17
548	Psychotropic drug-induced weight gain and other metabolic complications in a Swiss psychiatric population. 2012 , 46, 540-8		29
547	Better understanding of mechanisms of schizophrenia and bipolar disorder: from human gene expression profiles to mouse models. 2012 , 45, 48-56		23
546	Cardiovascular side-effects of antipsychotic drugs: the role of the autonomic nervous system. 2012 , 135, 113-22		99
545	[Metabolic disorders under antipsychotic treatment]. 2012 , 83, 337-44		1
544	Homocysteine levels in patients with schizophrenia on clozapine monotherapy. 2013 , 38, 2056-62		11
543	A randomized, 12-week study of the effects of extended-release paliperidone (paliperidone ER) and olanzapine on metabolic profile, weight, insulin resistance, and B cell function in schizophrenic patients. 2013 , 230, 3-13		20
542	A behavioral weight-loss intervention in persons with serious mental illness. 2013 , 368, 1594-602		362
541	Assessment of cardiovascular disease risk in patients with schizophrenia spectrum disorders in German psychiatric hospitals: results of the pharmacoepidemiologic CATS study. 2013 , 48, 1283-8		6
540	The prevalence of metabolic syndrome amongst patients with severe mental illness in the community in Hong Kong--a cross sectional study. <i>BMC Psychiatry</i> , 2013 , 13, 87	4.2	25
539	Management of Medication-Related Cardiometabolic Risk in Patients with Severe Mental Illness. 2013 , 7, 283-287		10
538	The comparison of glycometabolism parameters and lipid profiles between drug-naïve, first-episode schizophrenia patients and healthy controls. <i>Schizophrenia Research</i> , 2013 , 150, 157-62	3.6	63
537	Antipsychotic-induced metabolic and cardiovascular side effects in schizophrenia: a novel mechanistic hypothesis. 2013 , 27, 249-57		53
536	Atypical antipsychotics and effects of adrenergic and serotonergic receptor binding on insulin secretion in-vivo: an animal model. <i>Schizophrenia Research</i> , 2013 , 146, 162-9	3.6	20
535	Psychological and physical self-management of people with schizophrenia in community psychiatric rehabilitation settings: a qualitative study. 2013 , 19 Suppl 2, 24-33		1
534	Optimizing outcomes for persons with schizophrenia minimizing adverse effects and individualizing treatment. 2013 , 6, 437-8		
533	Associations between health risk behaviors and symptoms of schizophrenia and bipolar disorder: a systematic review. 2013 , 35, 16-22		44
532	Diabète et santé mentale. 2013 , 37, S459-S465		0

531	The role of consultation-liaison psychiatrists in improving health care of patients with schizophrenia. 2013 , 54, 22-7		9
530	Unraveling the relationship between obesity, schizophrenia and cognition. <i>Schizophrenia Research</i> , 2013 , 151, 107-12	3.6	27
529	Detection of metabolic syndrome in schizophrenia and implications for antipsychotic therapy : is there a role for folate?. 2013 , 17, 21-30		19
528	STRIDE: a randomized trial of a lifestyle intervention to promote weight loss among individuals taking antipsychotic medications. <i>BMC Psychiatry</i> , 2013 , 13, 238	4.2	23
527	Primary prevention of cardiovascular events in patients with major mental illness: a possible role for statins. 2013 , 15, 813-23		14
526	Implementation of a weight loss program for Latino outpatients with severe mental illness. 2013 , 49, 150-6		7
525	Primary care-based educational interventions to decrease risk factors for metabolic syndrome for adults with major psychotic and/or affective disorders: a systematic review. 2013 , 2, 116		13
524	Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease. 2013 , 62, 3232-40		122
523	Low levels of physical activity in patients with severe mental illness. 2013 , 67, 43-6		52
522	A randomized controlled trial undertaken to test a nurse-led weight management and exercise intervention designed for people with serious mental illness who take second generation antipsychotics. 2013 , 69, 1539-48		41
521	Évaluation de l'État de soi chez des patients bipolaires en rémission. 2013 , 28, 49-49		
520	Dépistage et prise en charge du syndrome métabolique chez des patients bénéficiant d'un neuroleptique d'action prolongé. 2013 , 28, 49-49		
519	Complexité diagnostique d'un syndrome catatonique en psychiatrie et neurologie : à propos d'un cas. 2013 , 28, 48-49		1
518	[Effectiveness of a joint project between primary care and mental health to improve the recording of cardiovascular risk factors in patients with psychosis]. 2013 , 45, 307-14		6
517	Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. <i>Schizophrenia Research</i> , 2013 , 145, 101-9	3.6	108
516	Total and differential white blood cell counts, high-sensitivity C-reactive protein, and the metabolic syndrome in non-affective psychoses. 2013 , 31, 82-9		42
515	Metabolic syndrome and antipsychotic monotherapy treatment among schizophrenia patients in Malaysia. 2013 , 57 Suppl, S50-3		7
514	Metabolic syndrome among schizophrenia patients: study from a rural community of south India. 2013 , 6, 532-6		6

513	C-reactive protein as a marker of cardiovascular disease in patients with a schizophrenia spectrum disorder treated in routine medical practice. 2013 , 28, 161-7		22
512	Prevalence of night eating in obese individuals with schizophrenia and schizoaffective disorder. 2013 , 54, 276-81		17
511	Increased Framingham 10-year CVD risk in Chinese patients with schizophrenia. <i>Schizophrenia Research</i> , 2013 , 147, 187-192	3.6	24
510	P.3.b.029 Antipsychotics, metabolic syndrome and schizophrenia: investigating the role of SREBF polymorphisms. 2013 , 23, S446		
509	A prospective, longitudinal study of metabolic syndrome in patients with bipolar disorder and schizophrenia. <i>Journal of Affective Disorders</i> , 2013 , 150, 653-8	6.6	30
508	A population-based cohort study to elucidate temporal relationship between schizophrenia and metabolic syndrome (KCIS no. PSY3). <i>Schizophrenia Research</i> , 2013 , 151, 158-64	3.6	6
507	Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial. <i>Schizophrenia Research</i> , 2013 , 146, 190-5	3.6	24
506	Diabetes and mental health. 2013 , 37 Suppl 1, S87-92		34
505	Crosstalk between 5-HT _{2c} R and PTEN signaling pathway in atypical antipsychotic-induced metabolic syndrome and cognitive dysfunction. 2013 , 80, 486-9		13
504	P.3.b.028 Transcultural study of clinical and psychosocial aspects of schizophrenia: comparison of patients in Armenia and Belarus. 2013 , 23, S445-S446		
503	Obese schizophrenia spectrum patients have significantly higher 10-year general cardiovascular risk and vascular ages than obese individuals without severe mental illness. 2013 , 54, 67-73		47
502	Racial patterns of cardiovascular disease risk factors in serious mental illness and the overall U.S. population. <i>Schizophrenia Research</i> , 2013 , 150, 211-6	3.6	20
501	Lipid effects of psychiatric medications. 2013 , 15, 292		2
500	Co-encapsulating nanostructured lipid carriers for transdermal application: from experimental design to the molecular detail. 2013 , 167, 301-14		98
499	Comparison of metabolic effects of ziprasidone versus olanzapine treatment in patients with first-episode schizophrenia. 2013 , 225, 627-35		25
498	Metabolic side-effects of the novel second-generation antipsychotic drugs asenapine and iloperidone: a comparison with olanzapine. 2013 , 8, e53459		27
497	Long-Chain Omega-3 Fatty Acids and Psychotic Disorders. 2013 , 149-178		
496	Metabolic syndrome and obsessive-compulsive disorder: a naturalistic Italian study. 2013 , 35, 154-9		42

495	Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data. 2013 , 16, 951-61	10
494	Primary care providers' views on metabolic monitoring of outpatients taking antipsychotic medication. 2013 , 64, 597-9	34
493	A comparison of assertive community treatment fidelity measures and patient-centered medical home standards. 2013 , 64, 1127-33	4
492	Metabolic syndrome: differences between psychiatric and internal medicine patients. 2013 , 45, 203-26	12
491	Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial. 2013 , 16, 987-95	60
490	Healthy living? By whose standards? Engaging mental health service recipients to understand their perspectives of, and barriers to, healthy living. 2013 , 36, 215-8	11
489	The sex-dependent impact of chronic clozapine and haloperidol treatment on characteristics of the metabolic syndrome in a rat model. 2013 , 46, 1-9	13
488	Metabolic syndrome in schizophrenia. 2013 , 35, 227-40	53
487	Metabolic syndrome in schizophrenia: Differences between antipsychotic-naïve and treated patients. 2013 , 4, 176-86	54
486	Prerequisites for a healthy lifestyle-experiences of persons with psychosis. 2013 , 34, 602-10	17
485	Family caregiving for adults with schizophrenia and diabetes mellitus. 2013 , 34, 566-77	6
484	The prevalence of glucose intolerance in Japanese schizophrenic patients with a normal fasting glucose level. 2013 , 33, 525-7	2
483	The prevalence of metabolic syndrome and its association with alanine aminotransferase in clozapine-treated Korean patients with schizophrenia. 2013 , 28, 71-9	5
482	Genetic variants of microsomal triglyceride transfer protein (MTTP) are associated with metabolic syndrome in schizophrenic patients treated with atypical antipsychotics. 2013 , 33, 313-8	5
481	The evaluation of a telephonic wellness coaching intervention for weight reduction and wellness improvement in a community-based cohort of persons with serious mental illness. 2013 , 201, 977-86	18
480	Bridging the gap from evidence to policy and practice: reducing the progression to metabolic syndrome for children and adolescents on antipsychotic medication. 2013 , 47, 435-42	14
479	The prevalence and mechanisms of metabolic syndrome in schizophrenia: a review. 2013 , 3, 33-51	69
478	A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls. 2013 , 12, 240-50	168

477	Olanzapine increases hepatic glucose production through the activation of hypothalamic adenosine 5'-monophosphate-activated protein kinase. 2013 , 15, 1128-35		37
476	Genetic association study between antipsychotic-induced weight gain and the melanocortin-4 receptor gene. 2013 , 13, 272-9		43
475	Improving physical health and reducing substance use in psychosis--randomised control trial (IMPACT RCT): study protocol for a cluster randomised controlled trial. <i>BMC Psychiatry</i> , 2013 , 13, 263	4.2	25
474	Prevalence of Metabolic Syndrome and Associated Risk Factors in Hospitalized Patients with Schizophrenia in Mexico. 2013 , 42, 95-104		3
473	Prevalence of metabolic syndrome and its association with depression in patients with schizophrenia. 2013 , 9, 941-6		25
472	A comparison of cardiovascular risk factors for ten antipsychotic drugs in clinical practice. 2013 , 9, 371-7		14
471	Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the US. 2013 , 5, 459-70		13
470	Improving health promotion in psychiatric inpatient settings. 2013 , 2, 204-210		2
469	An evaluation of the effects of the novel antipsychotic drug lurasidone on glucose tolerance and insulin resistance: a comparison with olanzapine. 2014 , 9, e107116		16
468	A qualitative study exploring facilitators for improved health behaviors and health behavior programs: mental health service users' perspectives. 2014 , 2014, 870497		10
467	Prevalence of metabolic syndrome according to the presence of negative symptoms in patients with schizophrenia. 2015 , 11, 51-7		27
466	The comparison of glucose and lipid metabolism parameters in drug-naïve, antipsychotic-treated, and antipsychotic discontinuation patients with schizophrenia. 2014 , 10, 1361-8		6
465	Yokukansan and its ingredients as possible treatment options for schizophrenia. 2014 , 10, 1629-34		5
464	HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: a meta-analysis. 2014 , 18, 229-42		23
463	Changing the obesogenic environment of severe mentally ill residential patients: ELIPS, a cluster randomised study design. <i>BMC Psychiatry</i> , 2014 , 14, 293	4.2	5
462	Contextual Factors in the Health of People With Serious Mental Illness. 2014 , 24, 1126-1137		21
461	Improving metabolic and cardiovascular health at an early psychosis intervention program in Vancouver, Canada. <i>Frontiers in Psychiatry</i> , 2014 , 5, 105	5	11
460	Physical health and mental illness. 2014 , 7, 716-722		1

459	Increased mortality in schizophrenia due to cardiovascular disease - a non-systematic review of epidemiology, possible causes, and interventions. <i>Frontiers in Psychiatry</i> , 2014 , 5, 137	5	184
458	Role of Atypical Antipsychotics in the Development of Metabolic Syndrome. 2014 , 1		1
457	Physical performance and disability in schizophrenia. <i>Schizophrenia Research: Cognition</i> , 2014 , 1, 112-121	2.8	38
456	The effect of ziprasidone on metabolic syndrome risk factors in subjects with schizophrenia: a 1 year, open-label, prospective study. 2014 , 30, 997-1005		4
455	Nonketotic hyperglycemia presenting as choreoathetosis in a female schizophrenia patient. 2014 , 26, E25-6		
454	Pharmacogenomics of sterol synthesis and statin use in schizophrenia subjects treated with antipsychotics. 2014 , 15, 61-7		9
453	Effects of olanzapine on the elevation of macrophage infiltration and pro-inflammatory cytokine expression in female rats. 2014 , 28, 1161-9		26
452	Screening for type 2 diabetes mellitus in patients with mental illness: application of a self-assessment score for diabetes mellitus risk. <i>Psychiatry Research</i> , 2014 , 220, 1037-42	9.9	4
451	Association of obesity and treated hypertension and diabetes with cognitive ability in bipolar disorder and schizophrenia. 2014 , 16, 422-31		53
450	Psychotic disorder is an independent risk factor for increased fasting glucose and waist circumference. 2014 , 68, 251-8		8
449	Community adherence to schizophrenia treatment and safety monitoring guidelines. 2014 , 202, 6-12		10
448	Metabolic profile and indices in a sample of drug-naive patients with schizophrenia and bipolar disorder. 2014 , 21, 22-27		1
447	Factors affecting costs in Medicaid populations with behavioral health disorders. 2014 , 52 Suppl 3, S60-6		13
446	A naturalistic comparison of the long-term metabolic adverse effects of clozapine versus other antipsychotics for patients with psychotic illnesses. 2014 , 34, 441-5		14
445	Pharmacological treatment of antipsychotic-induced dyslipidemia and hypertension. 2014 , 29, 125-37		31
444	Long-term mortality of persons with severe mental illness and diabetes: a population-based cohort study in Denmark. <i>Psychological Medicine</i> , 2014 , 44, 3097-107	6.9	37
443	Factors influencing cardiometabolic monitoring practices in an adult community mental health service. 2014 , 23, 479-89		10
442	Treatment resistance and other complicating factors in the management of schizophrenia. 2014 , 19 Suppl 1, 16-23; quiz 13-5, 24		7

441	The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia. 2014 , 48, 277-86		221
440	Cancer risk factors among adults with serious mental illness. 2014 , 46, S98-103		9
439	The concomitant use of second-generation antipsychotics and long-term antiretroviral therapy may be associated with increased cardiovascular risk. <i>Psychiatry Research</i> , 2014 , 218, 201-8	9.9	10
438	[Psychosis, cardiovascular risk and associated mortality: are we on the right track?]. 2014 , 26, 23-32		7
437	Comparative study of prevalence of metabolic syndrome in bipolar disorder and schizophrenia from North India. 2014 , 68, 72-7		23
436	Metabolic syndrome in patients taking clozapine: prevalence and influence of catechol-O-methyltransferase genotype. 2014 , 231, 2211-8		25
435	The effectiveness of lifestyle interventions to reduce cardiovascular risk in patients with severe mental disorders: meta-analysis of intervention studies. 2014 , 50, 81-95		45
434	Endothelial nitric oxide synthetase genetic variants, metabolic syndrome and endothelial function in schizophrenia. 2014 , 28, 349-56		25
433	Atypical antipsychotic-induced metabolic disturbances in the elderly. 2014 , 31, 159-84		11
432	The prevalence of metabolic syndrome in people with severe mental illness: a mediation analysis. 2014 , 49, 1739-46		37
431	Primary health care experiences of hispanics with serious mental illness: a mixed-methods study. 2014 , 41, 724-36		23
430	Routine exercise ameliorates the metabolic side-effects of treatment with the atypical antipsychotic drug olanzapine in rats. 2014 , 17, 77-90		32
429	Mortality in schizophrenia: clinical and serological predictors. 2014 , 40, 796-803		29
428	Maternal and newborn outcomes among women with schizophrenia: a retrospective population-based cohort study. 2014 , 121, 566-74		81
427	The metabolic syndrome and risk of coronary artery disease in patients with chronic schizophrenia or schizoaffective disorder in a chronic mental institute. 2014 , 30, 579-86		5
426	Flash sur la recommandation « soins somatiques en psychiatrie ». 2014 , 29, 589-590		
425	TDA/H et troubles du sommeil ^ l'âge adulte : revue de la littérature et particularités chronobiologiques. 2014 , 29, 588-589		
424	FFP âLe corps en psychiatrie. 2014 , 29, 589-589		

423	Le syndrome métabolique : prévalence et analyse des pratiques, résultats d'une expérience menée au CHRU de Brest. 2014 , 29, 568-568		0
422	General medical burden in bipolar disorder: findings from the LiTMUS comparative effectiveness trial. 2014 , 129, 24-34		58
421	Metabolic syndrome in bipolar disorder and schizophrenia: dietary and lifestyle factors compared to the general population. 2014 , 16, 277-88		62
420	Metabolic syndrome in psychiatry: advances in understanding and management. 2014 , 20, 101-112		19
419	Diet and exercise effects on aerobic fitness and body composition in seriously mentally ill adults. 2014 , 14, 620-7		5
418	The effectiveness of specialist roles in mental health metabolic monitoring: a retrospective cross-sectional comparison study. <i>BMC Psychiatry</i> , 2014 , 14, 234	4.2	29
417	Aminotransferase levels as a prospective predictor for the development of metabolic syndrome in patients with schizophrenia. 2014 , 231, 4479-87		2
416	Body mass index and metabolic parameters in patients with schizophrenia during long-term treatment with paliperidone palmitate. <i>BMC Psychiatry</i> , 2014 , 14, 52	4.2	11
415	Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. 2014 , 40, 1385-403		127
414	Screening for metabolic syndrome in older patients with severe mental illness. 2014 , 22, 1116-20		18
413	High fat diet produces brain insulin resistance, synaptodendritic abnormalities and altered behavior in mice. 2014 , 67, 79-87		184
412	Prevalence of cardiovascular risk factors among racial and ethnic minorities with schizophrenia spectrum and bipolar disorders: a critical literature review. 2014 , 55, 233-47		61
411	Asenapine increases nitric oxide release and protects porcine coronary artery endothelial cells against peroxidation. 2014 , 60, 127-41		16
410	Cost-effectiveness of second-generation antipsychotics for the treatment of schizophrenia. 2014 , 17, 310-9		14
409	Unhealthy lifestyle in early psychoses: the role of life stress and the hypothalamic-pituitary-adrenal axis. <i>Psychoneuroendocrinology</i> , 2014 , 39, 1-10	5	33
408	Association of FTO, LEPR and MTHFR gene polymorphisms with metabolic syndrome in schizophrenia patients receiving antipsychotics. 2014 , 15, 477-85		29
407	C-reactive protein levels in schizophrenia: a review and meta-analysis. 2014 , 7, 223-30		162
406	Metabolic Abnormality and Sleep Disturbance are Associated with Clinical Severity of Patients with Schizophrenia. 2014 , 4, 6		4

405	Cardiovascular Disease and Severe Mental Illness. 2014 , 54-65	1
404	Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. 2015 , 14, 119-36	432
403	The effect of folate supplementation and genotype on cardiovascular and epigenetic measures in schizophrenia subjects. 2015 , 1, 15046	14
402	Antipsychotic Drugs. 2015 , 2088-2128	
401	Obesity- and Neuroinflammation-Associated Mood and Cognitive Disorders. 2015 , 139-153	
400	Inequalities in physical comorbidity: a longitudinal comparative cohort study of people with severe mental illness in the UK. 2015 , 5, e009010	58
399	The Microbiome in Mental Health: Potential Contribution of Gut Microbiota in Disease and Pharmacotherapy Management. 2015 , 35, 910-6	33
398	Peer-led healthy lifestyle program in supportive housing: study protocol for a randomized controlled trial. 2015 , 16, 388	27
397	Metformin for Weight Gain and Metabolic Abnormalities Associated With Antipsychotic Treatment: Meta-Analysis of Randomized Placebo-Controlled Trials. 2015 , 35, 499-509	53
396	Diabetes and glucose disturbances in patients with psychosis in Sweden. 2015 , 3, e000120	4
395	Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia. 2015 , 30, 342-50	25
394	The prevention of diabetes and cardiovascular disease in people with schizophrenia. 2015 , 132, 86-96	19
393	. 2015 ,	1
392	Predictors of quality of life among individuals with schizophrenia. 2015 , 11, 1371-9	20
391	Understanding antipsychotic-induced weight gain and other metabolic issues. 2015 , 4, 157-166	1
390	Etiology of cardiovascular disease in patients with schizophrenia: current perspectives. 2015 , 11, 2493-503	30
389	Associations between components of metabolic syndrome and cognition in patients with schizophrenia. 2015 , 21, 190-7	20
388	A Study on Changes of Metabolic Parameters with Antipsychotic Treatment in Schizophrenic Patients : 1 Year Prospective Naturalistic Study. 2015 , 18, 59	

387	Increased cardiometabolic dysfunction in first-degree relatives of patients with psychotic disorders. <i>Schizophrenia Research</i> , 2015 , 165, 103-7	3.6	27
386	Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study. 2015 , 11, 685-93		16
385	Total and differential white blood cell counts, inflammatory markers, adipokines, and the metabolic syndrome in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. <i>Schizophrenia Research</i> , 2015 , 169, 30-35	3.6	18
384	Metabolic Syndrome Screening and Assertive Community Treatment: A Quality Improvement Study. <i>Journal of the American Psychiatric Nurses Association</i> , 2015 , 21, 233-43	1.8	7
383	Olanzapine Is Faster than Haloperidol in Inducing Metabolic Abnormalities in Schizophrenic and Bipolar Patients. 2015 , 72, 29-36		6
382	No changes of cardiometabolic and body composition parameters after 6-month add-on treatment with sarcosine in patients with schizophrenia. <i>Psychiatry Research</i> , 2015 , 230, 200-4	9.9	6
381	Effects of high-intensity aerobic exercise on psychotic symptoms and neurocognition in outpatients with schizophrenia: study protocol for a randomized controlled trial. 2015 , 16, 557		15
380	Changes in brain regions associated with food-intake regulation, body mass and metabolic profiles during acute antipsychotic treatment in first-episode schizophrenia. 2015 , 233, 186-93		9
379	Treatment of clozapine-associated weight gain: a systematic review. 2015 , 71, 389-401		33
378	Changes in body mass and metabolic profiles in patients with first-episode schizophrenia treated for 12 months with a first-generation antipsychotic. 2015 , 30, 277-83		21
377	Total and differential white blood cell counts, high-sensitivity C-reactive protein, and cardiovascular risk in non-affective psychoses. 2015 , 45, 28-35		24
376	GIPR Gene Polymorphism and Weight Gain in Patients With Schizophrenia Treated With Olanzapine. 2015 , 27, 162-4		7
375	The other 23 hours: a qualitative study of fitness provider perspectives on social support for health promotion for adults with mental illness. 2015 , 40, 91-9		6
374	Cardiovascular risk factors and metabolic syndrome in people with established psychotic illnesses: baseline data from the IMPaCT randomized controlled trial. <i>Psychological Medicine</i> , 2015 , 45, 2619-29	6.9	85
373	Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses. 2015 , 2, 452-464		146
372	Concomitant psychiatric problems and hormonal treatment induced metabolic syndrome in gender dysphoria individuals: a 2 year follow-up study. 2015 , 78, 399-406		42
371	Association of metabolic syndrome with sensory gating deficits in patients with chronic schizophrenia. <i>Psychoneuroendocrinology</i> , 2015 , 57, 125-33	5	5
370	Review of the evidence: prevalence of medical conditions in the United States population with serious mental illness. 2015 , 37, 199-222		88

369	Unrecognised myocardial infarction in patients with schizophrenia. 2015 , 27, 106-12		24
368	Uric acid levels in patients with schizophrenia on clozapine monotherapy. 2015 , 69, 453-8		4
367	Antipsychotic treatment reduces psychotic symptoms and markers of low-grade inflammation in first episode psychosis patients, but increases their body mass index. <i>Schizophrenia Research</i> , 2015 , 169, 22-29	3.6	42
366	Association of adipokines with metabolic disorders in patients with schizophrenia: Results of comparative study with mental healthy cohort. 2015 , 9, 163-7		9
365	Integrated Care at the Interface of Psychiatry and Primary Care: Prevention of Cardiovascular Disease. 2015 , 38, 463-74		1
364	Metabolic syndrome and aerobic fitness in patients with first-episode schizophrenia, including a 1-year follow-up. <i>Schizophrenia Research</i> , 2015 , 168, 381-7	3.6	30
363	Metformin attenuates olanzapine-induced hepatic, but not peripheral insulin resistance. 2015 , 227, 71-81		21
362	Antipsychotics-induced metabolic alterations: focus on adipose tissue and molecular mechanisms. 2015 , 25, 1-16		58
361	Diabetes mellitus and severe mental illness: mechanisms and clinical implications. 2015 , 11, 79-89		83
360	Is abnormal non-high-density lipoprotein cholesterol a gender-specific predictor for metabolic syndrome in patients with schizophrenia taking second-generation antipsychotics?. 2015 , 30, 107-13		6
359	Metabolic and inflammatory genes in schizophrenia. <i>Psychiatry Research</i> , 2015 , 225, 208-211	9.9	31
358	Factors associated with co-occurring medical conditions among adults with serious mental disorders. <i>Schizophrenia Research</i> , 2015 , 161, 458-64	3.6	29
357	Racial/Ethnic disparities in monitoring metabolic parameters for patients with schizophrenia receiving antipsychotic medications. 2015 , 23, 596-606		6
356	Effects and feasibility of the "traffic light method for somatic screening and lifestyle" in patients with severe mental illness: a pilot study. 2015 , 51, 106-13		12
355	Psychopathology in Women. 2015 ,		1
354	Soluble urokinase-type plasminogen activator receptor levels in patients with schizophrenia. 2015 , 41, 764-71		12
353	Amélioration de la santé cardiovasculaire par lâExercice physique chez les individus atteints de schizophr�ie : un guide de pratique. 2015 , 10, 4-20		2
352	Screening Patients with Severe Mental Illness for Metabolic Syndrome: A Quality Improvement Project by a Mobile Medication Nursing Program. 2016 , 2,		

351	Total white blood cell count, liver enzymes, and metabolic syndrome in schizophrenia. 2016 , 46, 259-64	1
350	Treating women with schizophrenia. 307-319	
349	Toward a Diathesis-Stress Model of Schizophrenia in a Neurodevelopmental Perspective. 2016 , 23, 209-224	
348	Cardio Metabolic Syndrome: A Global Epidemic. 2016 , 6,	14
347	High Prevalence of Obesity, Hypertension, Hyperlipidemia, and Diabetes Mellitus in Japanese Outpatients with Schizophrenia: A Nationwide Survey. 2016 , 11, e0166429	35
346	The prevalence and risk factors of stroke in patients with chronic schizophrenia. 2016 , 12, 1131-4	7
345	Psychotic disorders in women. 269-293	
344	Symptomatic Remission Determines Functional Improvement and Quality of Life in Schizophrenia. 2016 , 53, 328-333	4
343	Relationship between serum uric acid level and cardiometabolic risks in nondiabetic patients with schizophrenia. 2016 , 31, 51-6	1
342	A Naturalistic Randomized Placebo-Controlled Trial of Extended-Release Metformin to Prevent Weight Gain Associated With Olanzapine in a US Community-Dwelling Population. 2016 , 36, 163-8	15
341	Systematic review of self-management in patients with schizophrenia: psychometric assessment of tools, levels of self-management and associated factors. 2016 , 72, 2598-2611	14
340	Patient Safety Events and Harms During Medical and Surgical Hospitalizations for Persons With Serious Mental Illness. 2016 , 67, 1068-1075	12
339	The Rise of Primary Care Physicians in the Provision of US Mental Health Care. 2016 , 41, 559-83	26
338	Sex Differences in Body Mass Index and Obesity in Chinese Patients With Chronic Schizophrenia. 2016 , 36, 643-648	30
337	Metabolic Abnormalities Related to Treatment With Selective Serotonin Reuptake Inhibitors in Patients With Schizophrenia or Bipolar Disorder. 2016 , 36, 615-620	19
336	A Diet and Fitness Program Similarly Affects Weight Reduction in Schizophrenia Patients Treated with Typical or Atypical Medications. 2016 , 49, 112-6	9
335	Metabolic syndrome in people with a psychotic illness: is cannabis protective?. <i>Psychological Medicine</i> , 2016 , 46, 1651-62	6.9 15
334	Metabolomic Profiling of Post-Mortem Brain Reveals Changes in Amino Acid and Glucose Metabolism in Mental Illness Compared with Controls. 2016 , 14, 106-16	21

333	Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia. 2016 , 34, 709-21		9
332	Developing confidence in mental health students to recognise and manage physical health problems using a learning intervention. 2016 , 19, 25-30		8
331	From gut dysbiosis to altered brain function and mental illness: mechanisms and pathways. <i>Molecular Psychiatry</i> , 2016 , 21, 738-48	15.1	468
330	Prevalence of diagnosed ocular disease in veterans with serious mental illness. 2016 , 43, 1-5		4
329	Elevated plasma F2-isoprostane levels in schizophrenia. <i>Schizophrenia Research</i> , 2016 , 176, 320-326	3.6	28
328	Monitoring antipsychotic side effects: a completed audit cycle conducted in a secure hospital. 2016 , 18, 182-188		
327	Tolerability and Safety Profile of Cariprazine in Treating Psychotic Disorders, Bipolar Disorder and Major Depressive Disorder: A Systematic Review with Meta-Analysis of Randomized Controlled Trials. 2016 , 30, 1043-1054		26
326	Cardiometabolic health, prescribed antipsychotics and health-related quality of life in people with schizophrenia-spectrum disorders: a cross-sectional study. <i>BMC Psychiatry</i> , 2016 , 16, 411	4.2	22
325	Sex Differences in Weight Loss among Veterans with Serious Mental Illness: Observational Study of a National Weight Management Program. 2016 , 26, 410-9		9
324	Consideration of Clozapine and Gender-Affirming Medical Care for an HIV-Positive Person with Schizophrenia and Fluctuating Gender Identity. 2016 , 24, 406-415		3
323	Perceived needs and health-related quality of life in people with schizophrenia and metabolic syndrome: a "real-world" study. <i>BMC Psychiatry</i> , 2016 , 16, 414	4.2	3
322	Management of Older Inpatients Who Refuse Nonpsychiatric Medication Within Birmingham and Solihull Mental Health NHS Foundation Trust: Audit. 2016 , 204, 950-954		
321	Diabetes and Cardiovascular Care Among People with Severe Mental Illness: A Literature Review. 2016 , 31, 1083-91		49
320	Prevalence and determinants of metabolic syndrome in patients with schizophrenia: A systematic review and meta-analysis of Indian studies. 2016 , 22, 86-92		18
319	Associations Between Gender and Obesity Among Adults with Mental Illnesses in a Community Health Screening Study. 2016 , 52, 406-15		13
318	Metabolic syndrome in schizophrenia patients associated with poor premorbid school performance in early adolescence. 2016 , 133, 289-97		11
317	Efficacy of ranitidine in olanzapine-induced weight gain: a dose-response study. 2016 , 10, 522-527		5
316	Implementation of a Reverse Colocation Model: Lessons from Two Community Behavioral Health Agencies in Rural Pennsylvania. 2016 , 43, 443-58		7

315	Difference in prevalence of metabolic syndrome between Japanese outpatients and inpatients with schizophrenia: A nationwide survey. <i>Schizophrenia Research</i> , 2016 , 171, 68-73	3.6	20
314	Cardiovascular diseases among patients with schizophrenia. 2016 , 19, 28-36		31
313	Vitamin D in schizophrenia: a clinical review. 2016 , 19, 6-9		49
312	Exercise may benefit patients with schizophrenia. 2016 , 14, 103-114		5
311	A low TSH profile predicts olanzapine-induced weight gain and relief by adjunctive topiramate in healthy male volunteers. <i>Psychoneuroendocrinology</i> , 2016 , 66, 101-10	5	8
310	Physical activity in adolescents who later developed schizophrenia: A prospective case-control study from the Young-HUNT. 2016 , 70, 111-5		6
309	Molecular substrates of schizophrenia: homeostatic signaling to connectivity. <i>Molecular Psychiatry</i> , 2016 , 21, 10-28	15.1	58
308	A retrospective study of medical comorbidities in psychogeriatric patients. 2016 , 16, 12-9		8
307	Is there an interrelationship between the effects of antipsychotics on psychopathology and on metabolism?. 2016 , 70, 190-4		5
306	Quality of life and clinical characteristics in a nonselected sample of patients with schizophrenia. 2016 , 62, 12-20		13
305	Relationship Between Metabolic Syndrome and Clinical Features, and Its Personal-Social Performance in Patients with Schizophrenia. 2016 , 87, 265-80		6
304	Complement 3 and metabolic syndrome induced by clozapine: a cross-sectional study and retrospective cohort analysis. 2017 , 17, 92-97		16
303	Attending to physical health in mental health services in Australia: a qualitative study of service users' experiences and expectations. 2017 , 25, 602-611		18
302	A Randomized Controlled Trial of a Patient-Centered Approach to Improve Screening for the Metabolic Side Effects of Antipsychotic Medications. 2017 , 53, 163-175		9
301	Depot risperidone-induced adverse metabolic alterations in female rats. 2017 , 31, 487-499		8
300	Metabolic syndrome or glucose challenge in first episode of psychosis?. 2017 , 41, 42-46		14
299	Metabolic Syndrome Prevalence and Reduction in Inmates Prescribed Antipsychotic Medications. 2017 , 23, 203-213		4
298	Interactions between cannabis and schizophrenia in humans and rodents. 2017 , 28, 811-823		6

297	Patient Characteristics Associated with Inpatient Psychiatric Re-admissions and the Utility of the READMIT Clinical Risk Index. 2017 , 38, 411-419		4
296	The relationship between metabolic syndrome, BDNF, and vitamin D in patients with schizophrenia. 2017 , 11, 104-111		4
295	Risk of diabetes and dyslipidemia during clozapine and other antipsychotic drug treatment of schizophrenia in Iceland. 2017 , 71, 496-502		14
294	Risk excess of mortality and use of antipsychotics: a case-noncase study. 2017 , 32, 1-5		4
293	Twenty-year progression of body mass index in a county-wide cohort of people with schizophrenia and bipolar disorder identified at their first episode of psychosis. 2017 , 19, 336-343		34
292	Second-Generation Antipsychotics and Metabolic Side Effects: A Systematic Review of Population-Based Studies. 2017 , 40, 771-781		94
291	[Schizophrenia and oral health]. 2017 , 118, 115-118		
290	Patient, Provider, and System Factors Contributing to Patient Safety Events During Medical and Surgical Hospitalizations for Persons With Serious Mental Illness. 2017 , 205, 495-501		5
289	Interaction Between Atypical Antipsychotics and the Gut Microbiome in a Bipolar Disease Cohort. 2017 , 37, 261-267		141
288	The relationship between cognitive impairment in schizophrenia and metabolic syndrome: a systematic review and meta-analysis. <i>Psychological Medicine</i> , 2017 , 47, 1030-1040	6.9	94
287	Participants' Voices From Within a Healthy Lifestyle Group. 2017 , 38, 107-112		5
286	Psychiatric Care in Severe Obesity. 2017 ,		1
285	Simulated Effects of Policies to Reduce Diabetes Risk Among Adults With Schizophrenia Receiving Antipsychotics. 2017 , 68, 1280-1287		1
284	Changing the obesogenic environment to improve cardiometabolic health in residential patients with a severe mental illness: cluster randomised controlled trial. 2017 , 211, 296-303		13
283	Physical Health and Drug Safety in Individuals with Schizophrenia. 2017 , 62, 673-683		16
282	Cardiovascular Disease in Clozapine-Treated Patients: Evidence, Mechanisms and Management. 2017 , 31, 777-795		24
281	Metabolische Nebenwirkungen von Psychopharmaka. 2017 , 18, 44-52		
280	Increased serum brain-derived neurotrophic factor in male schizophrenic patients with metabolic syndrome. 2017 , 96, e7089		11

279	Inflammatory, cardio-metabolic and diabetic profiling of chronic schizophrenia. 2017 , 39, 1-10		33
278	Diabetes Knowledge Among Adults with Serious Mental Illness and Comorbid Diabetes Mellitus. 2017 , 31, 190-196		6
277	Cardiometabolic risk in first-episode schizophrenia (FES) patients with the earliest stages of both illness and antipsychotic treatment. <i>Schizophrenia Research</i> , 2017 , 179, 41-49	3.6	15
276	Health Education and Activity - Lessening The Inequalities in mental health (HEA - LTI mental health). 2017 , 6,		2
275	Refs. 2017 , 423-494		
274	Positive impact of prescribed physical activity on symptoms of schizophrenia: randomized clinical trial. 2017 , 29, 459-465		14
273	The Effects on Metabolic Syndrome Parameters of Atypical Antipsychotic Agents in Schizophrenics Patients : 3 Years Retrospective Follow Up. 2017 , 20, 5		
272	Modified Mediterranean Diet for Enrichment of Short Chain Fatty Acids: Potential Adjunctive Therapeutic to Target Immune and Metabolic Dysfunction in Schizophrenia?. 2017 , 11, 155		38
271	Intrinsic and Antipsychotic Drug-Induced Metabolic Dysfunction in Schizophrenia. 2017 , 11, 432		35
270	Exploring the long-term safety of asenapine in adults with schizophrenia in a double-blind, fixed-dose, extension study. 2017 , 13, 2021-2035		9
269	Utilization of the Behavior Change Wheel framework to develop a model to improve cardiometabolic screening for people with severe mental illness. 2017 , 12, 134		21
268	Metabolic Effects of Antidepressant Treatment. 2017 , 54, 49-56		15
267	Metabolic profile at first-time schizophrenia diagnosis: a population-based cross-sectional study. 2017 , 13, 621-630		8
266	The Prevalence of Metabolic Syndrome and Its Related Factors among Adults in Palestine: A Meta-Analysis. 2017 , 27, 77-84		15
265	High risk of metabolic syndrome among black South African women with severe mental illness. <i>South African Journal of Psychiatry</i> , 2017 , 23, 1089	1	3
264	A comparison of depot and oral atypical antipsychotics in terms of metabolic syndrome markers. 2018 , 28, 285-290		1
263	Cardio-metabolic risk and its management in a cohort of clozapine-treated outpatients. <i>Schizophrenia Research</i> , 2018 , 199, 367-373	3.6	19
262	Associations between clinical and psychosocial factors and metabolic and cardiovascular risk factors in overweight patients with schizophrenia spectrum disorders - Baseline and two-years findings from the CHANGE trial. <i>Schizophrenia Research</i> , 2018 , 199, 96-102	3.6	24

261	Diabetes and Mental Health. 2018 , 42 Suppl 1, S130-S141		42
260	Second generation antipsychotic-induced mitochondrial alterations: Implications for increased risk of metabolic syndrome in patients with schizophrenia. 2018 , 28, 369-380		27
259	Combined treatment with a selective PDE10A inhibitor TAK-063 and either haloperidol or olanzapine at subeffective doses produces potent antipsychotic-like effects without affecting plasma prolactin levels and cataleptic responses in rodents. 2018 , 6, e00372		6
258	Towards a comprehensive routine outcome monitoring program for people with psychotic disorders: The Pharmacotherapy Monitoring and Outcome Survey (PHAMOUS). <i>Schizophrenia Research</i> , 2018 , 197, 281-287	3.6	15
257	Genetic polymorphisms of HTR2C, LEP and LEPR on metabolic syndromes in patients treated with atypical antipsychotic drugs. 2018 , 70, 536-542		11
256	Cardiometabolic comorbidities and life expectancy in people on medication for schizophrenia in Australia. 2018 , 34, 613-618		7
255	The association of Mediterranean diet and exercise modifications with anthropometric parameters in a psychiatric community population: A pilot study. 2018 , 9, 68-71		3
254	Socioeconomic Disparities and Metabolic Risk in Veterans with Serious Mental Illness. 2018 , 54, 725-734		3
253	The association between rehabilitation programs and metabolic syndrome in chronic inpatients with schizophrenia. <i>Psychiatry Research</i> , 2018 , 260, 227-232	9.9	2
252	Higher schizotypy predicts better metabolic profile in unaffected siblings of patients with schizophrenia. 2018 , 235, 1029-1039		3
251	Implications of infection and trends of antibiotic prescribing in hospitalized patients diagnosed with serious mental illness. 2018 , 33, 49-55		1
250	A feasibility study of a physiotherapy-led motivational programme to increase physical activity and improve cardiometabolic risk in people with major mental illness. 2018 , 54, 37-44		2
249	Cardiometabolic risk factors, physical activity and psychiatric status in patients in long-term psychiatric inpatient departments. 2018 , 72, 296-302		31
248	Metabolic syndrome in antipsychotic naive African patients with severe mental illness in usual care. 2018 , 12, 1137-1143		6
247	Effects of the Thai Health Improvement Profile intervention on the physical health and health behaviours of people with schizophrenia: A quasi-experimental study. 2018 , 27, 126-137		7
246	Impact of a nurse practitioner role on metabolic monitoring completion and referrals for consumers admitted to the intensive care area of an acute inpatient psychiatric unit. 2018 , 27, 341-348		10
245	Application of plasma levels of olanzapine and N-desmethyl-olanzapine to monitor metabolic parameters in patients with schizophrenia. <i>Schizophrenia Research</i> , 2018 , 193, 139-145	3.6	16
244	Risperidone-induced metabolic dysfunction is attenuated by Curcuma longa extract administration in mice. 2018 , 33, 63-77		8

243	Chinese Health Improvement Profile for people with severe mental illness: A cluster-randomized, controlled trial. 2018 , 27, 841-855		11
242	Comparison of the G and V methods for ventrogluteal site identification: Muscle and subcutaneous fat thicknesses and considerations for successful intramuscular injection. 2018 , 27, 631-641		2
241	A Doctor is in the House: Stakeholder Focus Groups About Expanded Scope of Practice of Community Psychiatrists. 2018 , 54, 507-513		5
240	Decreased 5-HT _{2c} R and GHSR1a interaction in antipsychotic drug-induced obesity. 2018 , 19, 396-405		13
239	Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia. <i>Frontiers in Psychiatry</i> , 2018 , 9, 622	5	65
238	Bringing an Effective Behavioral Weight Loss Intervention for People With Serious Mental Illness to Scale. <i>Frontiers in Psychiatry</i> , 2018 , 9, 604	5	5
237	Higher mortality and years of potential life lost of suicide in patients with schizophrenia. <i>Psychiatry Research</i> , 2018 , 270, 531-537	9.9	17
236	Severe mental illness and chronic kidney disease: a cross-sectional study in the United Kingdom. 2018 , 10, 421-429		17
235	Cause, consequence or coincidence: The relationship between psychiatric disease and metabolic syndrome. 2018 , 1, 23-38		1
234	Obstructive Sleep Apnoea. 2018 , 213-238		
233	Continuity of Information Between Mental Health and Primary Care Providers After a Mental Health Consultation. 2018 , 69, 1081-1086		3
232	Metabolic Side Effects in Patients Using Atypical Antipsychotic Medications During Hospitalization. 2018 , 56, 28-37		7
231	Clozapine-Induced Cardiovascular Side Effects and Autonomic Dysfunction: A Systematic Review. 2018 , 12, 203		30
230	High-density lipoprotein-cholesterol and antipsychotic medication in overweight inpatients with schizophrenia: post-hoc analysis of a Japanese nationwide survey. <i>BMC Psychiatry</i> , 2018 , 18, 180	4.2	10
229	Second-generation antipsychotics and metabolic side-effects: Canadian population-based study. 2018 , 4, 256-261		6
228	Contribution of parasympathetic muscarinic augmentation of insulin secretion to olanzapine-induced hyperinsulinemia. 2018 , 315, E250-E257		8
227	Sleep Disorders in Psychiatric Patients. 2018 ,		2
226	Exploring shared genetic bases and causal relationships of schizophrenia and bipolar disorder with 28 cardiovascular and metabolic traits. <i>Psychological Medicine</i> , 2019 , 49, 1286-1298	6.9	22

225	Study protocol for a randomised controlled trial of CBT vs antipsychotics vs both in 14-18-year-olds: Managing Adolescent first episode Psychosis: a feasibility study (MAPS). 2019 , 20, 395		6
224	Atypical antipsychotics-induced metabolic syndrome and nonalcoholic fatty liver disease: a critical review. 2019 , 15, 2087-2099		35
223	Clinical Correlates of Insulin Resistance in Chronic Schizophrenia: Relationship to Negative Symptoms. <i>Frontiers in Psychiatry</i> , 2019 , 10, 251	5	6
222	Examination of heterogeneity in treatment response to antipsychotic medications. <i>Schizophrenia Research</i> , 2019 , 211, 100-102	3.6	
221	Associations among antipsychotics, metabolism-related diseases, and cataracts in patients with schizophrenia: A retrospective cohort study. <i>Schizophrenia Research</i> , 2019 , 212, 150-156	3.6	1
220	Sex-differential effects of olanzapine vs. aripiprazole on glucose and lipid metabolism in first-episode schizophrenia. 2019 , 46, 33-39		2
219	A Generic Automated Surface Defect Detection Based on a Bilinear Model. 2019 , 9, 3159		12
218	Prevalence of metabolic syndrome and its associated risk factors in an African-Caribbean population with severe mental illness. <i>Psychiatry Research</i> , 2019 , 281, 112558	9.9	5
217	Insomnia in patients with schizophrenia: current understanding and treatment options. 2019 , 92, 235-242		17
216	Cardiovascular risk remains high in schizophrenia with modest improvements in bipolar disorder during past decade. 2019 , 139, 348-360		17
215	Coronary artery disease and schizophrenia: the interplay of heart and mind. 2019 , 5, 90-91		1
214	Relationship of metabolic syndrome and neurocognitive deficits in patients with schizophrenia. <i>Psychiatry Research</i> , 2019 , 278, 56-64	9.9	8
213	Total and differential white blood cell counts, inflammatory markers, adipokines, and incident metabolic syndrome in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. <i>Schizophrenia Research</i> , 2019 , 209, 193-197	3.6	8
212	A novel approach to cardiovascular disturbances in patients with schizophrenia spectrum disorders treated with long-acting injectable medication. 2019 , 15, 349-355		5
211	Metabolic Side Effects of Antipsychotic Medication: An Overview. 2019 , 58, 18		
210	Effect of a Behavioral Weight Loss Intervention in People With Serious Mental Illness and Diabetes. 2019 , 42, 804-809		4
209	Association between thyroid function and metabolic syndrome in male and female schizophrenia patients. <i>Psychiatry Research</i> , 2019 , 274, 167-175	9.9	3
208	Opinions of Primary Care Clinicians and Psychiatrists on Monitoring the Metabolic Effects of Antipsychotics. 2019 , 32, 418-423		5

207	Prevalence and Associated Factors of Metabolic Syndrome among Patients with Severe Mental Illness Attending a Tertiary Hospital in Southwest Uganda. 2019 , 2019, 1096201		8
206	Orexin-A Levels in Relation to the Risk of Metabolic Syndrome in Patients with Schizophrenia Taking Antipsychotics. 2019 , 22, 28-36		11
205	Effects of Atypical Antipsychotic Treatment and Resistant Starch Supplementation on Gut Microbiome Composition in a Cohort of Patients with Bipolar Disorder or Schizophrenia. 2019 , 39, 161-170		51
204	High prevalence of metabolic alterations in Latin American patients at initial stages of psychosis. 2019 , 13, 1382-1388		2
203	Retrospective study of first episode psychosis in the Dublin Southwest Mental Health Service: demographics, clinical profile and service evaluation of treatment. 2019 , 36, 249-258		3
202	Antipsychotic treatment is associated with inflammatory and metabolic biomarkers alterations among first-episode psychosis patients: A 7-month follow-up study. 2019 , 13, 101-109		23
201	Metabolic Syndrome Screening in People With Severe Mental Illness: Results From Two Spanish Community Mental Health Centers. <i>Journal of the American Psychiatric Nurses Association</i> , 2020 , 26, 162-171	18	2
200	Cardiovascular Adverse Reactions During Antipsychotic Treatment: Results of AMSP, A Drug Surveillance Program Between 1993 and 2013. 2020 , 23, 67-75		9
199	Detecting schizophrenia early: Prediagnosis healthcare utilization characteristics of patients with schizophrenia may aid early detection. <i>Schizophrenia Research</i> , 2020 , 215, 392-398	3.6	3
198	The experience of body image concerns in patients with persecutory delusions: 'People don't want to sit next to me'. 2020 , 93, 639-655		7
197	Psychiatric drugs impact mitochondrial function in brain and other tissues. <i>Schizophrenia Research</i> , 2020 , 217, 136-147	3.6	10
196	The Gut Microbiome in Bipolar Disorder and Pharmacotherapy Management. 2020 , 79, 43-49		21
195	Meta-analysis of comorbid diabetes and family history of diabetes in non-affective psychosis. <i>Schizophrenia Research</i> , 2020 , 216, 41-47	3.6	9
194	Psychotic Disorders. 2020 ,		5
193	Normalizing the Abnormal: Do Antipsychotic Drugs Push the Cortex Into an Unsustainable Metabolic Envelope?. 2020 , 46, 484-495		9
192	FADS1 modulates metabolic syndrome in schizophrenia patients receiving olanzapine monotherapy. 2020 , 54, 102352		1
191	Cardio-metabolic abnormalities among patients with severe mental illness at a Regional Referral Hospital in southwestern Uganda. 2020 , 15, e0235956		2
190	Association Between SIRT1, Cytokines, and Metabolic Syndrome in Schizophrenia Patients With Olanzapine or Clozapine Monotherapy. <i>Frontiers in Psychiatry</i> , 2020 , 11, 602121	5	5

189	Physical health assessment and cardiometabolic monitoring practices across three adult mental health inpatient units - a retrospective cohort study. 2020 , 29, 1144-1156	1
188	Association of antipsychotics adherence and cardiovascular disease among newly diagnosed schizophrenia patients: A national cohort among Koreans. 2020 , 52, 102161	0
187	Improving rates of metabolic monitoring on an inpatient psychiatric ward. 2020 , 9,	3
186	Lurasidone and risk for metabolic syndrome: results from short- and long-term clinical studies in patients with schizophrenia. 2020 , 1-11	2
185	The Impact of Mental Illness on Postoperative Outcomes Among Medicare Beneficiaries: A Missed Opportunity to Help Surgical Patients?. 2020 , 272, 419-425	13
184	Metabolomic profiles associated with a mouse model of antipsychotic-induced food intake and weight gain. 2020 , 10, 18581	2
183	Cardiometabolic Risk in First Episode Psychosis Patients. 2020 , 11, 564240	4
182	Susceptibility of male wild type mouse strains to antipsychotic-induced weight gain. 2020 , 220, 112859	2
181	Why are cardiovascular diseases more common among patients with severe mental illness? The potential involvement of electronegative low-density lipoprotein (LDL) L5. 2020 , 142, 109821	4
180	References. 2020 , 245-390	
179	Medical comorbid diagnoses among adult psychiatric inpatients. 2020 , 66, 16-23	4
178	Birth weight, family history of diabetes and diabetes onset in schizophrenia. 2020 , 8,	4
177	Sex differences in the association of body mass index with symptoms and cognitive deficits in Chinese patients with chronic schizophrenia. 2020 , 10, 18	18
176	Association study of candidate genes with obesity and metabolic traits in antipsychotic-treated patients with first-episode psychosis over a 2-year period. 2020 , 34, 514-523	8
175	Metabolic Syndrome and Cognitive Functions in Schizophrenia-Implementation of Dietary Intervention. <i>Frontiers in Psychiatry</i> , 2020 , 11, 359	5 7
174	Metabolic screen and intervene: improving mental health inpatient metabolic monitoring. 2021 , 29, 289-293	1
173	Sex differences in metabolic disorder patterns of first-episode drug-naive patients with schizophrenia. <i>Psychoneuroendocrinology</i> , 2021 , 124, 105061	5 11
172	Safety and effectiveness of oral blonanserin for schizophrenia: A review of Japanese post-marketing surveillances. 2021 , 145, 42-51	5

171	Higher prevalence of metabolic syndrome and related factors in patients with first-episode psychosis and schizophrenia: a cross-sectional study in Turkey. 2021 , 75, 73-78	7
170	A Model for Advancing Scale-Up of Complex Interventions for Vulnerable Populations: the ALACRITY Center for Health and Longevity in Mental Illness. 2021 , 36, 500-505	1
169	The Gut Microbiome in Serious Mental Illnesses. 2021 , 243-263	
168	Integrated Review of Lifestyle Interventions Targeting Diet and Exercise in Early or First-Episode Psychosis. 2021 , 11, 265-278	0
167	References. 2021 , 499-522	
166	Binge Eating Disorders in Antipsychotic-Treated Patients With Schizophrenia: Prevalence, Antipsychotic Specificities, and Changes Over Time. 2021 , 41, 114-120	4
165	A Review of Switching Strategies for Patients with Schizophrenia Comorbid with Metabolic Syndrome or Metabolic Abnormalities. 2021 , 17, 453-469	1
164	Estrogens in schizophrenia: progress, current challenges and opportunities. 2021 , 34, 228-237	12
163	The Association Between Metabolic Disturbance and Cognitive Impairments in Early-Stage Schizophrenia. 2020 , 14, 599720	0
162	Guidelines to understand and compute the number needed to treat. 2021 , 24, 131-136	1
161	Assessment of metabolic risk factors in patients undergoing antipsychotic drug therapy: A Pharmacist-led study. 2021 , 56, 361-361	1
160	The role of pharmacy in the management of cardiometabolic risk, metabolic syndrome and related diseases in severe mental illness: a mixed-methods systematic literature review. 2021 , 10, 92	6
159	Improving cognition in severe mental illness by combining cognitive remediation and transcranial direct current stimulation: study protocol for a pragmatic randomized controlled pilot trial (HEADSET). 2021 , 22, 275	1
158	Targeting Personal Recovery of People With Complex Mental Health Needs: The Development of a Psychosocial Intervention Through User-Centered Design. <i>Frontiers in Psychiatry</i> , 2021 , 12, 635514	5 2
157	Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies. 2021 , 17, 957-970	12
156	Examining the effects of national initiatives to improve the physical health of people with psychosis in England: secondary analysis of data from the National Clinical Audit of Psychosis. 2021 , 1-8	0
155	Sleeve gastrectomy improves metabolic syndrome in psychologically stable patients with schizophrenia. 2021 , 7,	
154	Evidence for the atherogenic index of plasma as a potential biomarker for cardiovascular disease in schizophrenia. 2021 , 35, 1120-1126	2

153	Age-Specific Prevalence and Incidence of Dementia Diagnoses Among Older US Adults With Schizophrenia. 2021 , 78, 632-641		10
152	Effect of Nurse-Led Counseling on Maintenance of Healthy Lifestyle Among Outpatients Receiving Antipsychotics: Clinical Case Reports. 025371762110212		
151	Patient adherence with infection control measures on a novel 'COVID-19 triage' psychiatric in-patient ward. 2021 , 7, e131		3
150	Unveiling the Metabolic Profile of First-Episode Drug-Naïve Schizophrenia Patients: Baseline Characteristics of a Longitudinal Study Among Han Chinese. <i>Frontiers in Psychiatry</i> , 2021 , 12, 702720	5	1
149	Imbalance Model of Heart Rate Variability and Pulse Wave Velocity in Psychotic and Nonpsychotic Disorders. 2021 ,		1
148	Conserved immunomodulatory transcriptional networks underlie antipsychotic-induced weight gain. 2021 , 11, 405		0
147	Synthesized difference in differences. 2021 ,		
146	Prevalence of metabolic syndrome and associated factors among psychiatric patients at University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia. 2021 , 16, e0256195		0
145	Metabolomics-based understanding of the olanzapine-induced weight gain in female first-episode drug-naïve patients with schizophrenia. 2021 , 140, 409-415		3
144	The Outcomes of Acute Coronary Syndrome in Patients Suffering From Schizophrenia: A Systematic Review. 2021 , 13, e16998		
143	Levels of Interleukin 6 as a Predictor of Metabolic Syndrome in Schizophrenic Patients Receiving Combination Therapy of Typical and Atypical Antipsychotics. 2020 , 9, 600-607		1
142	The prevalence and clinical correlates of metabolic syndrome and cardiometabolic alterations in 430 drug-naïve patients in their first episode of schizophrenia. 2021 , 238, 3643-3652		1
141	Metabolic syndrome in antipsychotic-naïve patients with first-episode psychosis: a systematic review and meta-analysis. <i>Psychological Medicine</i> , 2021 , 51, 2307-2320	6.9	1
140	The association between chronotype and sleep quality, and cardiometabolic markers in patients with schizophrenia. 2021 , 1-12		1
139	Atypical antipsychotic drugs deregulate the cholesterol metabolism of macrophage-foam cells by activating NOX-ROS-PPAR α CD36 signaling pathway. 2021 , 123, 154847		2
138	Lipid Metabolism Disturbances During Antipsychotic Treatment for Schizophrenia. 2021 , 1-18		
137	Psychological intervention, antipsychotic medication or a combined treatment for adolescents with a first episode of psychosis: the MAPS feasibility three-arm RCT. 2021 , 25, 1-124		2
136	The Schizophrenia Construct: Symptomatic Presentation. 09-23		7

135	Behavioral Interventions to Improve Management of Overweight, Obesity, and Diabetes in Patients with Schizophrenia. 2008 , 171-186	1
134	Psychological Co-morbidities of Obesity. 2011 , 1-72	4
133	Psychological Issues in Adults with Type 2 Diabetes. 2011 , 73-121	12
132	Integrated Care and Psychiatrists. 2012 , 163-175	3
131	Prevalence of Psychiatric Symptoms/Syndromes in Medical Settings. 2014 , 5-27	5
130	Antipsychotics: Nonmotor Side Effects. 2020 , 201-214	2
129	Behavioural Interventions for Weight Management Among Patients with Schizophrenia. 2017 , 257-273	1
128	Psychosis and Schizophrenia. 2008 , 371-389	1
127	A Population-Based Cohort Study on Peripheral Arterial Disease in Patients with Schizophrenia. 2016 , 11, e0148759	3
126	Metabolic Syndrome in South African Patients with Severe Mental Illness: Prevalence and Associated Risk Factors. 2016 , 11, e0149209	26
125	Clinical pharmacology and vascular risk. 2010 , 4, 64-72	2
124	Clinical and Cost Consequences of Metabolic Effects of Lurasidone Versus Other Atypical Antipsychotics in Schizophrenia. 2014 , 1, 1-9	2
123	Long-term administration of olanzapine induces adiposity and increases hepatic fatty acid desaturation protein in female C57BL/6J mice. 2018 , 21, 495-501	12
122	Personalized prescribing: a new medical model for clinical implementation of psychotropic drugs. 2016 , 18, 313-322	11
121	Do higher primary care practice performance scores predict lower rates of emergency admissions for persons with serious mental illness? An analysis of secondary panel data. 2015 , 3, 1-68	4
120	A health promotion intervention to improve lifestyle choices and health outcomes in people with psychosis: a research programme including the IMPaCT RCT. 2020 , 8, 1-124	2
119	Weight Loss Interventions for Patients with Schizophrenia. 2007 , 1, 43-53	5
118	Comparison of Antipsychotics for Metabolic Problems (CAMP): A NIMH Schizophrenia Trials Network Study. 2007 , 1, 69-72	4

117	An Archival, Follow-Forward Exploration of the Metabolic Syndrome in Randomly Selected, Clozapine-Treated Patients. 2009 , 3, 87-96	5
116	Incidence and costs of cardiometabolic conditions in patients with schizophrenia treated with antipsychotic medications. 2010 , 4, 161-8	23
115	Ziprasidone's effect on metabolic markers in patients with diabetes and chronic schizophrenia. 2012 , 5, 185-92	5
114	Early Intervention in Psychosis: Effectiveness and Implementation of a Combined Exercise and Health Behavior Intervention Within Routine Care. 2020 , 11, 577691	4
113	The contribution of abdominal obesity and dyslipidemia to metabolic syndrome in psychiatric patients. 2010 , 25, 168-73	9
112	Body Mass Index Dependent Metabolic Syndrome in Severe Mental Illness Patients. 2014 , 8, 19-26	1
111	Epidemiology of Obesity. 2011 , 41, 484-488	6
110	Treatment settings and metabolic monitoring for people experiencing first-episode psychosis. 2010 , 48, 44-9	6
109	Lifestyle and Behavioral Interventions to Reduce the Risk of Metabolic Syndrome in Community-Dwelling Adults With Serious Mental Illness: Implications for Nursing Practice. 2016 , 54, 46-55	1
108	A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone. 2009 , 70, 487-99	46
107	Prevalence of metabolic syndrome in a predominantly cuban, psychiatrically ill, and homeless population. 2011 , 13,	2
106	Vitamin d status and cardiometabolic risk factors in long-term psychiatric inpatients. 2012 , 14,	2
105	Descriptive analysis of a novel health care approach: reverse colocation-primary care in a community mental health "home". 2013 , 15,	11
104	Metabolic adverse events in patients with mental illness treated with antipsychotics: a primary care perspective. 2008 , 10, 15-24	19
103	Metabolic syndrome in patients with severe mental illness in Gorgan. 2016 , 7, 62-7	5
102	WEIGHT GAIN AND ANTIPSYCHOTICS. DATA FROM EUFEST STUDY. 2016 , 12, 177-184	4
101	Association Between Age at Onset of Schizophrenia and Age at Menarche. 2014 , 51, 211-215	5
100	Relationship between SSRIs and Metabolic Syndrome Abnormalities in Patients with Generalized Anxiety Disorder: A Prospective Study. 2013 , 10, 148-54	36

- 99 Prevalence of Metabolic Syndrome in Patients with Schizophrenia in Korea: A Multicenter Nationwide Cross-Sectional Study. **2017**, 14, 44-50 17
- 98 Prevalence of Metabolic Syndrome in Patients with Schizophrenia Referred to Farabi Hospital, Kermanshah, Iran. **2016**, 31, 270-5 9
- 97 Association between the HTR2C rs1414334 C/G gene polymorphism and the development of the metabolic syndrome in patients treated with atypical antipsychotics. **2016**, 4, e2163 4
- 96 Prevalence of Metabolic Syndrome among Psychiatric Inpatients: A Hospital Based Study from Kashmir. **2017**, 11, VC05-VC08 10
- 95 Re-implementation of a pharmacist-managed metabolic syndrome clinic in an outpatient mental health clinic setting. **2015**, 5, 57-62 2
- 94 Are cardiometabolic and endocrine abnormalities linked to sleep difficulties in schizophrenia? A hypothesis driven review. **2012**, 10, 1-12 7
- 93 The prevalence of metabolic syndrome in schizophrenic patients using antipsychotics. **2013**, 11, 80-8 27
- 92 Metabolic disturbances associated with antipsychotic drug treatment in patients with schizophrenia: State-of-the-art and future perspectives. **2021**, 11, 696-710 2
- 91 Sex-Specific Effect of Serum Lipids and Body Mass Index on Psychotic Symptoms, a Cross-Sectional Study of First-Episode Psychosis Patients. *Frontiers in Psychiatry*, **2021**, 12, 723158 5
- 90 Onset of obstructive sleep apnea after initiation of psychotropic agents. **2007**, 9, 471 1
- 89 Chronic Mental Illness. **2008**, 887-893
- 88 Síndrome metabólico en pacientes ambulatorios con tratamiento antipsicótico en la práctica clínica habitual: evaluación transversal de una base de datos de atención primaria. **2008**, 15, 219-227
- 87 Highlights from The Twelfth Biennial International Congress on Schizophrenia Research, San Diego, CA March 28-April 1, 2009. **2009**, 3, 80-86
- 86 First episode schizophrenia: Considerations on the timing, selection, and duration of antipsychotic therapies. **2009**, 201-217
- 85 Schizophrenia: Differential diagnosis and comorbidities. **2009**, 52-69
- 84 Clinical psychopharmacology. **2010**, 227-294
- 83 Psychological Co-morbidities of Cardiovascular Disease. **2011**, 123-162
- 82 Schizophrenia and the Metabolic Syndrome. **2011**, 2617-2626

- 81 Metabolic Syndrome and Mental Illness. 177-193
- 80 Antipsychotika. **2012**, 659-693 1
- 79 The Negative Impact of the Misdiagnosis of Schizophrenia upon Patients, Their Families, and Their Caretakers. **2012**, 297-351 1
- 78 Psychiatric Disorders. **2012**, 931-965
- 77 4. Physical Risks Induced by Novel Antipsychotics and Preventive Measures. **2012**, 43, 151-156
- 76 Neuropsychopharmacology. **2012**, 664-702
- 75 Regional disease characteristics and comorbidities of patients with schizophrenia in the Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC): Findings from an international large simple trial. **2012**, 02, 423-432
- 74 The clinical needs of women with schizophrenia. **2012**, 183-201
- 73 Psychopharmacological management of schizophrenia. **2012**, 1-31
- 72 The clinical needs of women with schizophrenia. **2012**, 183-201
- 71 Psychopharmacological management of schizophrenia. **2012**, 1-31
- 70 Organization of Care and Treatment. **2013**, 69-156
- 69 Schizophrenie und Diabetes. **2013**, 225-231
- 68 Inflammation-Mediated Cognitive and Emotional Alterations in Experimental Models of Metabolic Syndrome. 515-527
- 67 The Development and Implementation of an Electronic Health Record Tool for Monitoring Metabolic Syndrome Indices in Patients with Serious Mental Illness. **2013**, 1-25
- 66 Schizophrenia and Gender. **2015**, 621-639 0
- 65 Is Metabolic Syndrome On the Radar? Improving Real-Time Detection of Metabolic Syndrome and Physician Response by Computerized Scan of the Electronic Medical Record. **2016**, 18, 2
- 64 Chovňsouisejťse zdravĕm: determinanty, modely a konsekvence. **2016**, 0

63	Psychosis: Schizophrenia and Related Disorders. 2018 , 335-372	
62	İzofreni hastalarında fiziksel hastalık eġanfanfıñ deġlendirilmesi. 2018 , 43, 892-902	1
61	Essential Medical Work-Up and Rule Outs. 2019 , 3-25	
60	Schizophrenia: effects of aripiprazole in metabolic syndrome. 55,	0
59	Schizophrenia and Gender. 2019 , 715-737	
58	Functional analysis of evolutionary human methylated regions in schizophrenia patients.	
57	Frequency of occurrence of type 2 diabetes and metabolic disturbances in patients with schizophrenic range disorders with prolonged anti-relapse antipsychotic therapy (based on screening results). 2019 , 37-45	
56	Eating and nutritional habits in patients with schizophrenia. 2019 ,	1
55	Electroconvulsive Therapy as a Corrector for Certain Side Effects of Antipsychotic Therapy. 2020 , 5, 55-82	
54	The prevalence of cardiometabolic disease in people with psychotic disorders in secure settings âġ systematic review. 2021 , 32, 281-307	4
53	Obesity and schizophrenia: New drugs, new hopes. 2020 , 52, 113-130	
52	İzofreni tanġhastalarda metabolik sendrom ve D vitamini dġeyleri iliġisi. 2019 , 44, 1110-1117	
51	Association of selected antipsychotics on the triglyceride levels in patients with schizophrenia in inpatient and outpatient settings. 2020 , 11, 15-22	
50	Antipsychotika. 2008 , 591-625	1
49	A review of bipolar disorder in adults. 2006 , 3, 43-55	10
48	Commentary. 2012 , 3, 284-5	
47	Cardiometabolic consequences of therapy for chronic schizophrenia using second-generation antipsychotic agents in a medicaid population: clinical and economic evaluation. 2013 , 38, 109-15	11
46	Sex Differences in Antipsychotic Related Metabolic Functioning in Schizophrenia Spectrum Disorders. 2017 , 47, 8-21	11

45	Insomnia and triglycerides in schizophrenia. <i>Schizophrenia Research</i> , 2021 , 239, 42-43	3.6	0
44	Metabolic syndrome and associated factors among severely ill psychiatric and non-psychiatric patients: a comparative cross-sectional study in Eastern Ethiopia. <i>Diabetology and Metabolic Syndrome</i> , 2021 , 13, 130	5.6	
43	Antipsychotic medication for women with schizophrenia spectrum disorders. <i>Psychological Medicine</i> , 2021 , 1-15	6.9	5
42	Decreased serum S100A10 levels in patients with both schizophrenia and metabolic syndrome. <i>Taiwanese Journal of Psychiatry</i> , 2020 , 34, 110	0.4	
41	The benefits of the Mediterranean diet in first episode psychosis patients taking antipsychotics.. <i>Toxicology Reports</i> , 2022 , 9, 120-125	4.8	1
40	Eating and nutritional habits in patients with schizophrenia.. <i>Revista De Psiquiatria Y Salud Mental (English Edition)</i> , 2022 ,	0.2	
39	Prevalence of metabolic syndrome among patients with schizophrenia in Ethiopia.. <i>BMC Psychiatry</i> , 2021 , 21, 620	4.2	2
38	Mental disorders in patients with metabolic syndrome. The key role of central obesity. <i>Eating and Weight Disorders</i> , 2012 , 17, e259-66	3.6	10
37	METABOLIC EFFECTS OF ANTIPSYCHOTIC TREATMENT IN SCHIZOPHRENIA. 2022 , 14-16		
36	Influence of first- and second-generation antipsychotics on anthropometric parameters of male psychiatric patients.. <i>South African Journal of Psychiatry</i> , 2022 , 28, 1772	1	
35	Influence of first- and second-generation antipsychotics on anthropometric parameters of male psychiatric patients. <i>South African Journal of Psychiatry</i> , 28,	1	
34	Does the gut microbiome mediate antipsychotic-induced metabolic side effects in schizophrenia?. <i>Expert Opinion on Drug Safety</i> , 2022 , 1-15	4.1	0
33	Antipsychotic-Related Risks of Type 2 Diabetes Mellitus in Enrollees With Schizophrenia in the National Basic Public Health Service Program in Hunan Province, China.. <i>Frontiers in Psychiatry</i> , 2022 , 13, 754775	5	1
32	Perceptions of ACT Team Members on the Implementation of Physical Health Services: A Qualitative Study.. <i>Journal of the American Psychiatric Nurses Association</i> , 2022 , 10783903221079800	1.8	
31	Gender and Body Mass Index-Related Serum Level of Adipokines and Metabolic Syndrome Components in Bipolar Patients who received Lithium and Valproic Acid. <i>Metabolic Syndrome and Related Disorders</i> , 2021 , 1-9	2.6	0
30	Gender Differences in Gut Microbiome Composition Between Schizophrenia Patients With Normal Body Weight and Central Obesity.. <i>Frontiers in Psychiatry</i> , 2022 , 13, 836896	5	
29	Exploring heterogeneity in meat consumption and eating out by using a latent class model. <i>British Food Journal</i> , 2022 , ahead-of-print,	2.8	0
28	Immuno-metabolic profile of patients with psychotic disorders and metabolic syndrome. Results from the FACE-SZ cohort.. <i>Brain, Behavior, & Immunity - Health</i> , 2022 , 22, 100436	5.1	0

27	The National Heart Lung and Blood Institute Disparities Elimination through Coordinated Interventions to Prevent and Control Heart and Lung Disease Alliance.. <i>Health Services Research</i> , 2022 ,	3.4	o
26	Orexin-a elevation in antipsychotic-treated compared to drug-free patients with schizophrenia: A medication effect independent of metabolic syndrome.. <i>Journal of the Formosan Medical Association</i> , 2022 ,	3.2	o
25	Allostatic load and systemic comorbidities in psychiatric disorders.. <i>Psychoneuroendocrinology</i> , 2022 , 140, 105726	5	o
24	Get up! Functional mobility and metabolic syndrome in chronic schizophrenia: Effects on cognition and quality of life.. <i>Schizophrenia Research: Cognition</i> , 2022 , 28, 100245	2.8	
23	Antipsychotic Drug-Induced Increases in Peripheral Catecholamines are Associated With Glucose Intolerance.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 765905	5.6	o
22	Table1.docx. 2018 ,		
21	Table_1.docx. 2018 ,		
20	Sex differences in antipsychotic-related triglyceride levels are associated with metabolic hormone differences in patients with severe mental disorders.. <i>Schizophrenia Research</i> , 2022 , 243, 55-63	3.6	
19	METABOLIC SYNDROME IN PATIENTS WITH PSYCHOSIS USING SECOND-GENERATION ANTIPSYCHOTICS. 2022 , 33-35		
18	Gut Microbial Dysbiosis and Cognitive Impairment in Bipolar Disorder: Current Evidence. <i>Frontiers in Pharmacology</i> , 13,	5.6	o
17	Relevance of interactions between dopamine and glutamate neurotransmission in schizophrenia. <i>Molecular Psychiatry</i> ,	15.1	2
16	Long-term treatment of antipsychotics and combined therapy with other psychotropic medications inducing weight gain in patients with non-affective psychotic disorder: Evidence from GROUP, a longitudinal study. <i>Psychiatry Research</i> , 2022 , 314, 114680	9.9	o
15	Sex Differences in and Pharmacotherapy of Schizophrenia.		
14	Oxidative stress parameters and antioxidants in adults with unipolar or bipolar depression versus healthy controls: Systematic review and meta-analysis. <i>Journal of Affective Disorders</i> , 2022 , 314, 211-221	6.6	2
13	Blood and Urinary Biomarkers of Antipsychotic-Induced Metabolic Syndrome. 2022 , 12, 726		o
12	National trends in metabolic risk of psychiatric inpatients in the United States during the atypical antipsychotic era. 2022 , 248, 320-328		o
11	Associations between adherence to the MIND diet and prevalence of psychological disorders, and sleep disorders severity among obese and overweight women: A cross-sectional study. 026010602211274		o
10	Metformin ameliorates olanzapine-induced obesity and glucose intolerance by regulating hypothalamic inflammation and microglial activation in female mice. 13,		o

- 9 Reduction in Multiple Cardiometabolic Risk Factors With Combined Olanzapine/Samidorphan Compared With Olanzapine: Post Hoc Analyses From a 24-Week Phase 3 Study. ○
- 8 Lipid Metabolism Disturbances During Antipsychotic Treatment for Schizophrenia. **2022**, 987-1004 ○
- 7 Adolescent raloxifene treatment in females prevents cognitive deficits in a neurodevelopmental rodent model of schizophrenia. **2022**, 114276 1
- 6 Prevalence of the metabolic syndrome and associated factors among inpatients with severe mental illness in Botswana: a cross-sectional study. **2022**, 22, ○
- 5 Thermoneutral housing and preexisting obesity do not abolish the sexually dimorphic effects of olanzapine on weight gain in mice. ○
- 4 Antipsychotic-induced alterations in lipid turnover. ○
- 3 Predictors of Antipsychotics Switching among Ambulatory Patients with Schizophrenia in Ethiopia: A Multicenter Hospital-Based Cross-Sectional Study.. ○
- 2 Metabolic biomarkers of risperidone-induced weight gain in drug-naïve patients with schizophrenia. 14, ○
- 1 Special aspects in the pharmacotherapeutic treatment of forensically hospitalized female patients. ○